var title_f15_33_15888="Morphea treatment algorithm";
var content_f15_33_15888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Treatment algorithm for morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 669px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Therapeutic algorithm for morphea based on existing evidence. Superficial involvement is defined by histological evidence of papillary dermal involvement. Deep involvement is defined as sclerosis or inflammation of the deep dermis, subcutis, fascia, or muscle. Histological examination and/or MRI are used to evaluate lesions for depth of involvement and, likewise, determine appropriate treatment as well as evaluation of therapeutic efficacy.",
"    <div class=\"footnotes\">",
"     NB UVB: narrowband; UVB BB UVB: broad band UVB.",
"     <br>",
"      * There is very little evidence for any therapy addressing disease damage in morphea. The risk of disease reactivation is also unknown, but possible with the use of invasive procedures. Therefore, surgery and the like should only be undertaken after prolonged inactivity of disease.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15888=[""].join("\n");
var outline_f15_33_15888=null;
var title_f15_33_15889="Ultrasound of an omphalocele";
var content_f15_33_15889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse section of the abdomen of a 28-week fetus with an omphalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrow points to omphalocele sac containing fluid and fetal liver.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15889=[""].join("\n");
var outline_f15_33_15889=null;
var title_f15_33_15890="Patient information: When your baby is overdue (The Basics)";
var content_f15_33_15890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15859\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/21/16723\">",
"         Patient information: C-section (cesarean delivery) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/2/19490\">",
"         Patient information: Shoulder dystocia (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/45/11988\">",
"         Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/38/26209\">",
"         Patient information: Postterm pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: When your baby is overdue (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/when-your-baby-is-overdue-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7448050\">",
"      <span class=\"h1\">",
"       How does my doctor or nurse figure out my due date?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To figure out your due date, your doctor or nurse counts 40 weeks from the first day of your last monthly period.",
"     </p>",
"     <p>",
"      If your periods are not regular, counting won&rsquo;t give a correct due date. In that case, your doctor or nurse will do an imaging test called an ultrasound to figure out your due date. An ultrasound can create pictures of your baby when it is inside your body. Your doctor can use these pictures to measure your baby&rsquo;s size and figure out your due date.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7448057\">",
"      <span class=\"h1\">",
"       When is a baby overdue?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A baby is overdue if he or she has not been born by 42 weeks (2 weeks after the due date). A pregnancy that lasts longer than 42 weeks is also called a &ldquo;postterm pregnancy&rdquo; or &ldquo;postdated pregnancy.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7448064\">",
"      <span class=\"h1\">",
"       What can cause a baby to be overdue?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors don&rsquo;t usually know. But a woman has a higher chance of having her baby after the due date if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        It&rsquo;s her first pregnancy",
"       </li>",
"       <li>",
"        She&rsquo;s already had a baby that was born after its due date",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7448071\">",
"      <span class=\"h1\">",
"       Why is it a problem for babies to be born after 42 weeks?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Babies born after 42 weeks have a higher chance of having problems, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Being too big (heavier than 10 pounds) &mdash; A big baby can get hurt if it cannot easily fit through the vagina (",
"        <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"         figure 1",
"        </a>",
"        ). A big baby can also damage the mother&rsquo;s body when it comes out through the vagina. Sometimes, the mother has to have a c-section (surgery to get the baby out).",
"       </li>",
"       <li>",
"        Having a bowel movement before birth &mdash; Babies who breathe in some of their bowel movement can have breathing problems after they are born.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other problems that can happen are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The placenta might not work as well as it did earlier in the pregnancy &mdash; The placenta is the organ that brings the baby nutrients and oxygen and carries away waste.",
"       </li>",
"       <li>",
"        There can be too little amniotic fluid (water) surrounding the baby in the uterus &mdash; If there is not enough amniotic fluid, the umbilical cord can get squeezed. If the umbilical cord is squeezed, the baby might not get enough oxygen and nutrients from the placenta.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7448078\">",
"      <span class=\"h1\">",
"       What happens if I am still pregnant after my due date?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are still pregnant after your due date, your doctor or nurse will do tests to check your baby&rsquo;s health. Most doctors and nurses do these tests at 41 or 42 weeks, but some women have these tests earlier. The tests can check:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your baby&rsquo;s heartbeat",
"       </li>",
"       <li>",
"        Your baby&rsquo;s breathing and movements",
"       </li>",
"       <li>",
"        The amount of amniotic fluid that surrounds your baby in the uterus",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on the test results and how far along your pregnancy is, your doctor might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Let your pregnancy continue until your body is ready to give birth",
"       </li>",
"       <li>",
"        Recommend that you have the baby soon",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7448085\">",
"      <span class=\"h1\">",
"       What if my doctor or nurse recommends that I have my baby soon?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor or nurse recommends that you have your baby soon, he or she will discuss your choices.",
"     </p>",
"     <p>",
"      If your body isn&rsquo;t ready to give birth, your doctor can give you medicines to help start your labor. When doctors use medicines to help start a woman&rsquo;s labor, they call it &ldquo;inducing labor.&rdquo; These medicines often work.",
"     </p>",
"     <p>",
"      Your doctor can also do a c-section to deliver your baby. A woman might have a c-section if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to induce labor don&rsquo;t work",
"       </li>",
"       <li>",
"        Her baby is too big to safely fit through her vagina",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7448092\">",
"      <span class=\"h1\">",
"       Will my baby be healthy if he or she is born after the due date?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most babies born after their due date are healthy. But babies born after their due date can look a little different at birth and have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Long and thin arms or legs",
"       </li>",
"       <li>",
"        Dry or peeling skin",
"       </li>",
"       <li>",
"        Long hair and nails",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7448099\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/2/19490?source=see_link\">",
"       Patient information: Shoulder dystocia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/38/26209?source=see_link\">",
"       Patient information: Postterm pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/33/15890?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15859 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-F836DB8729-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15890=[""].join("\n");
var outline_f15_33_15890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448050\">",
"      How does my doctor or nurse figure out my due date?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448057\">",
"      When is a baby overdue?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448064\">",
"      What can cause a baby to be overdue?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448071\">",
"      Why is it a problem for babies to be born after 42 weeks?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448078\">",
"      What happens if I am still pregnant after my due date?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448085\">",
"      What if my doctor or nurse recommends that I have my baby soon?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448092\">",
"      Will my baby be healthy if he or she is born after the due date?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7448099\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/38/26209?source=related_link\">",
"      Patient information: Postterm pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/2/19490?source=related_link\">",
"      Patient information: Shoulder dystocia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_33_15891="Indium In-111 pentetreotide: Patient drug information";
var content_f15_33_15891=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Indium In-111 pentetreotide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32050?source=see_link\">",
"     see \"Indium In-111 pentetreotide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14877563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      OctreoScan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13316699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a test to check for tumors.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13316670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to indium In-111 pentetreotide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13316672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13316702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13316674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13316701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13316703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13316675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17077 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15891=[""].join("\n");
var outline_f15_33_15891=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14877563\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316699\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316670\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316672\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316702\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316674\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316701\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316703\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13316675\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32050?source=related_link\">",
"      Indium In-111 pentetreotide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_33_15892="CT scan normal appendix";
var content_f15_33_15892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    CT scan normal appendix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan depicts a normal appendix. The figure on the left shows an appendiceal lumen containing air and wall thickness of 3 mm (yellow arrow). The figure on the right shows the tip of the normal appendix (green arrow) that measures 6 mm and no associated induration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15892=[""].join("\n");
var outline_f15_33_15892=null;
var title_f15_33_15893="Pericardiocentesis sites";
var content_f15_33_15893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Pericardiocentesis sites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the picture above, possible needle entry sites for emergency pericardiocentesis are designated by red dots. Emergency pericardiocentesis is most commonly performed using the left intercostal, left parasternal, or apical approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Picture courtesy of Robert Reardon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15893=[""].join("\n");
var outline_f15_33_15893=null;
var title_f15_33_15894="Arterial blood gases";
var content_f15_33_15894=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arterial blood gases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/33/15894/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15894/contributors\">",
"     Arthur C Theodore, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/33/15894/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15894/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/33/15894/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15894/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/33/15894/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An arterial blood gas (ABG) is a test that measures the oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ), carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ), acidity (pH), oxyhemoglobin saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    ), and bicarbonate (HCO",
"    <sub>",
"     3",
"    </sub>",
"    ) concentration in arterial blood. Some blood gas analyzers also measure the methemoglobin, carboxyhemoglobin, and hemoglobin levels. Such information is vital when caring for patients with critical illness or respiratory disease. As a result, the ABG is one of the most common tests performed on patients in intensive care units (ICUs).",
"   </p>",
"   <p>",
"    The sites, techniques, and complications of arterial sampling are reviewed here, as well as the transport and analysis of the arterial blood. Normal ABG values are provided and a common clinical situation in which the ABG results may be misleading is also described. Interpretation of abnormal ABG values and venous blood gases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=see_link\">",
"     \"Venous blood gases and other alternatives to arterial blood gases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ARTERIAL SAMPLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial blood is required for an ABG. It can be obtained by percutaneous needle puncture or from an indwelling arterial catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Needle puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous needle puncture refers to the withdrawal of arterial blood via a needle stick. It needs to be repeated every time an ABG is performed, since an indwelling catheter is not inserted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Site selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in percutaneous needle puncture is locating a palpable artery. Common sites include the radial, femoral, brachial, dorsalis pedis, or axillary artery. There is no evidence that any site is superior to the others. However, the radial artery is used most often because it is accessible, easily positioned, and more comfortable for the patient than the alternative sites.",
"   </p>",
"   <p>",
"    The radial artery is best palpated between the distal radius and the tendon of the flexor carpi radialis when the wrist is extended (",
"    <a class=\"graphic graphic_figure graphicRef55221 \" href=\"UTD.htm?10/1/10260\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82119 \" href=\"UTD.htm?8/17/8464\">",
"     figure 2",
"    </a>",
"    ). To get the wrist into this position, the arm should be positioned on an armboard with the palm facing upward and a large roll of gauze should be placed between the wrist and the armboard in a position that extends the wrist. Taping the forearm and palm to the armboard helps maintain the position.",
"   </p>",
"   <p>",
"    The brachial artery is best palpated medial to the biceps tendon in the antecubital fossa, when the arm is extended and the palm is facing up (",
"    <a class=\"graphic graphic_figure graphicRef57543 \" href=\"UTD.htm?34/44/35533\">",
"     figure 3",
"    </a>",
"    ). The needle should be inserted just above the elbow crease (",
"    <a class=\"graphic graphic_figure graphicRef69312 \" href=\"UTD.htm?3/19/3390\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The femoral artery is best palpated just below the midpoint of the inguinal ligament, when the lower extremity is extended (",
"    <a class=\"graphic graphic_figure graphicRef75120 \" href=\"UTD.htm?15/15/15600\">",
"     figure 5",
"    </a>",
"    ). The needle should be inserted at a 90 degree angle just below the inguinal ligament (",
"    <a class=\"graphic graphic_figure graphicRef50204 \" href=\"UTD.htm?37/51/38704\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The dorsalis pedis artery is best palpated lateral to the extensor hallucis longus tendon (",
"    <a class=\"graphic graphic_figure graphicRef54240 \" href=\"UTD.htm?38/43/39604\">",
"     figure 7",
"    </a>",
"    ). It receives collateral flow from the lateral plantar artery through an arch similar to that in the hand.",
"   </p>",
"   <p>",
"    The axillary artery is best palpated in the axilla, when the arm is abducted and externally rotated (",
"    <a class=\"graphic graphic_figure graphicRef55334 \" href=\"UTD.htm?9/58/10150\">",
"     figure 8",
"    </a>",
"    ). There is good collateral flow to the arm through the thyrocervical trunk and subscapular artery; thus, the risk of ischemic complications to the arm is low. The needle should be inserted as high into the axilla as possible (",
"    <a class=\"graphic graphic_figure graphicRef67106 \" href=\"UTD.htm?33/13/34014\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Collateral circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that patients undergoing radial or dorsalis pedis artery puncture should have the collateral flow to those vessels evaluated prior to puncture, even though studies have found variable accuracy associated with such evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Our belief is based upon the notion that the evaluation can be performed quickly at the bedside at no cost and with little risk for harm, but has substantial potential for benefit (ie, to identify patients who have impaired collateral circulation and, therefore, may be at increased risk of an ischemic complication).",
"   </p>",
"   <p>",
"    The Allen test or modified Allen test can be performed in patients undergoing radial artery puncture. These are bedside tests that demonstrate collateral flow through the superficial palmar arch [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To perform the modified Allen test, the patient's hand is initially held high with the fist clenched and both the radial and ulnar arteries compressed (",
"    <a class=\"graphic graphic_figure graphicRef70306 \" href=\"UTD.htm?3/61/4049\">",
"     figure 10",
"    </a>",
"    ). This allows the blood to drain from the hand. The hand is then lowered, the fist is opened, and pressure is released from the ulnar artery. Color should return to the hand within six seconds, indicating that the ulnar artery is patent and the superficial palmar arch is intact. The test is considered abnormal if ten seconds or more elapses before color returns to the hand (",
"    <a class=\"graphic graphic_picture graphicRef79685 \" href=\"UTD.htm?39/52/40771\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The Allen test (from which the modified Allen test evolved) is performed identically, except these steps are executed twice: once with release of pressure from the ulnar artery and once with release of pressure from the radial artery.",
"   </p>",
"   <p>",
"    For patients undergoing dorsalis pedis artery puncture, the dorsalis pedis artery can be occluded, followed by compression of the nailbed of the great toe and assessment of the rapidity with which color returns to the nailbed after pressure is released from the great toe (",
"    <a class=\"graphic graphic_figure graphicRef67077 \" href=\"UTD.htm?1/37/1616\">",
"     figure 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a palpable artery has been located, blood is withdrawn using the following steps.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The planned puncture site should be sterilely prepped.",
"     </li>",
"     <li>",
"      Local analgesia prior to arterial puncture should be considered, since it appears to prevent pain without adversely impacting the success of the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/4\">",
"       4",
"      </a>",
"      ]. This was illustrated by a trial that randomly assigned 101 patients undergoing arterial puncture to receive 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , normal saline, or no agent prior to the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/5\">",
"       5",
"      </a>",
"      ]. The lidocaine decreased pain without increasing the difficulty of the procedure (ie, the number of attempts), compared to the other groups.",
"     </li>",
"     <li>",
"      The seal of a heparinized syringe should be broken by pulling its plunger. The plunger can then be pushed back into the syringe, leaving a small empty volume (eg, less than 1 mL) in the syringe. A small needle (eg, 22 to 25 gauge) should then be attached to the syringe. Arterial blood gas kits are available, which contain a heparinized plastic syringe with the plunger already pulled back to allow for the collection of 2 mL of blood without the need to break the seal.",
"     </li>",
"     <li>",
"      Using one hand to gently palpate the artery and the other to manipulate the syringe and needle, the artery should be punctured with the needle at a 30 to 45 degree angle relative to the skin. The syringe will fill on its own (ie, pulling the plunger is unnecessary). Approximately 2 to 3 mL of blood should be removed.",
"     </li>",
"     <li>",
"      To prevent coagulation, the syringe should be rolled between the hands for a few seconds to allow blood to mix with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      After withdrawing a sufficient volume of blood, the needle should be removed and pressure applied to the puncture site for five to ten minutes to achieve hemostasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications due to percutaneous needle puncture are rare. They include persistent bleeding, bruising, and injury to the blood vessel. Circulation distal to the puncture site may also be impaired following percutaneous needle puncture, presumably due to thrombosis at the puncture site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Indwelling catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial blood can also be obtained via an indwelling arterial catheter. Indwelling catheters provide continuous access to arterial blood, which is helpful when frequent blood gases are needed (eg, respiratory failure). Insertion, complications, and use of an arterial catheter are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=see_link\">",
"     \"Arterial catheterization techniques for invasive monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPECIMEN CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the method used to withdraw the arterial blood, several issues should be considered prior to sending the specimen to the laboratory:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gas diffusion through the plastic syringe is a potential source of error. However, it appears that the clinical significance of the error is minimal if the sample is placed on ice and analyzed within 15 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/6-9\">",
"       6-9",
"      </a>",
"      ]. Using a glass syringe will also prevent this error.",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      that is added to the syringe as an anticoagulant can decrease in the pH if acidic heparin is used. It can also dilute the PaCO",
"      <sub>",
"       2",
"      </sub>",
"      , resulting in a falsely low value [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/6,10\">",
"       6,10",
"      </a>",
"      ]. Thus, the amount of heparin solution should be minimized and at least 2 mL of blood should be obtained.",
"     </li>",
"     <li>",
"      Air bubbles that exceed 1 to 2 percent of the blood volume can cause a falsely high PaO",
"      <sub>",
"       2",
"      </sub>",
"      and a falsely low PaCO",
"      <sub>",
"       2",
"      </sub>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/11\">",
"       11",
"      </a>",
"      ]. The magnitude of this error depends upon the difference in gas tensions between blood and air, the exposure surface area (which is increased by agitation), and the time from specimen collection to analysis. The clinical significance of this error can be decreased by gently removing the bubbles without agitation and analyzing the sample as soon as possible [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/7,12\">",
"       7,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TRANSPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arterial blood should be placed on ice during transport to the lab and then analyzed as quickly as possible. This reduces oxygen consumption by leukocytes (ie, leukocyte larceny), which can cause a factitiously low PaO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/13\">",
"     13",
"    </a>",
"    ]. This effect is most pronounced in patients whose leukocytosis is profound. In addition, it reduces the likelihood that error due to gas diffusion through the plastic syringe or air bubbles will be clinically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of arterial blood is usually performed by automated blood gas analyzers, which automatically transport the specimen to electrochemical sensors to measure pH, PaCO",
"    <sub>",
"     2",
"    </sub>",
"    , and PaO",
"    <sub>",
"     2",
"    </sub>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PaCO",
"      <sub>",
"       2",
"      </sub>",
"      is measured using a chemical reaction that consumes CO",
"      <sub>",
"       2",
"      </sub>",
"      and produces a hydrogen ion, which is sensed as a change in pH [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The PaO",
"      <sub>",
"       2",
"      </sub>",
"      is measured using oxidation-reduction reactions that generate measurable electric currents [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Automated blood gas analyzers rinse the system, calibrate the sensors, and report the results. Rigorous quality control by the laboratory is essential for accurate results.",
"   </p>",
"   <p>",
"    Arterial blood gas measurements are effected by temperature. Specifically, pH increases and both PaO",
"    <sub>",
"     2",
"    </sub>",
"    and PaCO",
"    <sub>",
"     2",
"    </sub>",
"    decrease as temperature declines (",
"    <a class=\"graphic graphic_table graphicRef59630 \" href=\"UTD.htm?5/45/5852\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Modern automated blood gas analyzers can report the pH, PaO",
"    <sub>",
"     2",
"    </sub>",
"    , and PaCO",
"    <sub>",
"     2",
"    </sub>",
"    at either 37&ordm;C (the temperature at which the values are measured by the blood gas analyzer) or at the patient's body temperature. Most centers report the values of pH, PCO",
"    <sub>",
"     2",
"    </sub>",
"    , and PO",
"    <sub>",
"     2",
"    </sub>",
"    at 37&ordm;C, even if the patient's body temperature is different. However, this practice is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABGs provide information about oxygenation, ventilation, and acid-base balance, which are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .) This section provides the normal values of ABG measurement and describes and common clinical situation in which the ABG results may be misleading.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28435429\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of normal values varies among laboratories. Generally speaking, the normal pH is 7.36 to 7.44, the normal PCO",
"    <sub>",
"     2",
"    </sub>",
"    is 36 to 44 mmHg, and the normal HCO",
"    <sub>",
"     3",
"    </sub>",
"    concentration is 21 to 27",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    Normal PaO",
"    <sub>",
"     2",
"    </sub>",
"    and SaO",
"    <sub>",
"     2",
"    </sub>",
"    have not been defined because a threshold below which tissue hypoxia occurs has not been identified. It seems reasonable to consider a resting PaO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;80 mmHg and SaO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;95 percent normal, unless the new values are substantially different than prior values. As an example, an SaO",
"    <sub>",
"     2",
"    </sub>",
"    of 96 percent may be abnormal if the patient&rsquo;s previous SaO",
"    <sub>",
"     2",
"    </sub>",
"    was 100 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link&amp;anchor=H2#H2\">",
"     \"Oxygenation and mechanisms of hypoxemia\", section on 'Measures of oxygenation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28435458\">",
"    <span class=\"h2\">",
"     Misleading results",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABGs estimate the systemic acid-base balance. However, arterial values may not reflect the acid-base status at the tissue level in settings where the cardiac output is markedly reduced (eg, circulatory failure or cardiopulmonary resuscitation) and lactic acidosis is present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. This was demonstrated by a study performed during cardiopulmonary resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/18\">",
"     18",
"    </a>",
"    ]. When blood was drawn simultaneously from an arterial catheter and a pulmonary artery catheter, the arterial pH and PCO",
"    <sub>",
"     2",
"    </sub>",
"    were 7.42 and 32 mmHg, while the respective mixed venous values were 7.14 and 74 mmHg. If the latter results more closely reflect the acid-base status at the tissue level, as is likely, then the arterial measurements can lead to the mistaken assumption that acid-base balance is being maintained.",
"   </p>",
"   <p>",
"    In this situation, the arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    is normal or reduced because ventilation is maintained, allowing the blood delivered to the lungs to be normally cleared of CO",
"    <sub>",
"     2",
"    </sub>",
"    . However, the mixed venous PCO",
"    <sub>",
"     2",
"    </sub>",
"    is markedly elevated because decreased systemic and pulmonary blood flow has diminished CO",
"    <sub>",
"     2",
"    </sub>",
"    delivery to the lungs and allowed CO",
"    <sub>",
"     2",
"    </sub>",
"    accumulation in the tissues. This problem of CO",
"    <sub>",
"     2",
"    </sub>",
"    accumulation in the tissues requires the restoration of adequate tissue perfusion. The administration of bicarbonate may exacerbate the problem because buffering of excess hydrogen ions by the exogenous bicarbonate results in increased CO",
"    <sub>",
"     2",
"    </sub>",
"    generation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15894/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear if a similar disparity between the arterial and mixed venous PCO",
"    <sub>",
"     2",
"    </sub>",
"    and pH occurs in septic shock. The cardiac output is typically above normal during the hyperdynamic phase of this disorder, but is still insufficient to meet tissue needs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3781?source=see_link\">",
"     \"Causes of lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An arterial blood gas (ABG) is a test that measures the arterial oxygen tension (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ), carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ), and acidity (pH). In addition, arterial oxyhemoglobin saturation (SaO",
"      <sub>",
"       2",
"      </sub>",
"      ) and serum bicarbonate (HCO",
"      <sub>",
"       3",
"      </sub>",
"      ) concentration can be determined. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous needle puncture is one method of obtaining the arterial blood necessary for an ABG (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Arterial sampling'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Common sites include the radial, femoral, brachial, dorsalis pedis, or axillary artery. There is no evidence that any site is superior to the others. However, the radial artery is used most often because it is accessible, easily positioned, and more comfortable for the patient than the alternative sites. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Site selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing radial or dorsalis pedis artery puncture, we suggest evaluating the collateral flow to those vessels prior to puncture (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Collateral circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the target artery has been identified, the planned puncture site should be sterilely prepped. The artery should be punctured with a small needle and syringe, 2 to 3 mL of blood should be withdrawn, and then needle should be removed. Finally, pressure should be applied to the puncture site for five to ten minutes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the administration of local analgesia prior to arterial puncture (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Local analgesia prevents pain without adversely impacting the success of the procedure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications due to percutaneous needle puncture are rare, but include persistent bleeding, bruising, and injury to the blood vessel. Circulation distal to the puncture site may also be impaired. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternatively, an indwelling arterial catheter can be used to obtain arterial blood for an ABG. An indwelling catheter provides continuous access to arterial blood. Arterial catheterization is discussed in greater detail separately. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Indwelling catheters'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=see_link\">",
"       \"Arterial catheterization techniques for invasive monitoring\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Regardless of the method used to withdraw the arterial blood, the amount of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      solution should be minimized, at least 2 mL of blood should be obtained, air bubbles should be removed, and the specimen should immediately be placed on ice and analyzed as quickly as possible. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Specimen care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Transport'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The range of normal values varies among laboratories. Generally speaking, the normal pH is 7.36 to 7.44, the normal PCO",
"      <sub>",
"       2",
"      </sub>",
"      is 36 to 44 mmHg, and the normal HCO",
"      <sub>",
"       3",
"      </sub>",
"      concentration is 21 to 27",
"      <span class=\"nowrap\">",
"       mEq/L.",
"      </span>",
"      Normal PaO",
"      <sub>",
"       2",
"      </sub>",
"      and SaO",
"      <sub>",
"       2",
"      </sub>",
"      have not been defined; however, it seems reasonable to consider a resting PaO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;80 mmHg and SaO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;95 percent normal, unless the new values are substantially different than prior values. (See",
"      <a class=\"local\" href=\"#H28435429\">",
"       'Normal values'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ABGs estimate the systemic acid-base balance. However, arterial values may not reflect the acid-base status at the tissue level in settings where the cardiac output is markedly reduced (eg, circulatory failure or cardiopulmonary resuscitation). It is unclear if a similar disparity occurs in septic shock. (See",
"      <a class=\"local\" href=\"#H28435458\">",
"       'Misleading results'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/1\">",
"      Kohonen M, Teerenhovi O, Terho T, et al. Is the Allen test reliable enough? Eur J Cardiothorac Surg 2007; 32:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/2\">",
"      Jarvis MA, Jarvis CL, Jones PR, Spyt TJ. Reliability of Allen's test in selection of patients for radial artery harvest. Ann Thorac Surg 2000; 70:1362.",
"     </a>",
"    </li>",
"    <li>",
"     Kaye W. Invasive monitoring techniques. In: Textbook of Advanced Cardiac Life Support, American Heart Association, Dallas.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/4\">",
"      Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994; 88:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/5\">",
"      Lightowler JV, Elliott MW. Local anaesthetic infiltration prior to arterial puncture for blood gas analysis: a survey of current practice and a randomised double blind placebo controlled trial. J R Coll Physicians Lond 1997; 31:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/6\">",
"      Bageant, RA. Variations in arterial blood gas measurements due to sampling techniques. Respir Care 1975; 20:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/7\">",
"      Harsten A, Berg B, Inerot S, Muth L. Importance of correct handling of samples for the results of blood gas analysis. Acta Anaesthesiol Scand 1988; 32:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/8\">",
"      Evers W, Racz GB, Levy AA. A comparative study of plastic (polypropylene) and glass syringes in blood-gas analysis. Anesth Analg 1972; 51:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/9\">",
"      Smeenk FW, Janssen JD, Arends BJ, et al. Effects of four different methods of sampling arterial blood and storage time on gas tensions and shunt calculation in the 100% oxygen test. Eur Respir J 1997; 10:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/10\">",
"      Hansen JE, Simmons DH. A systematic error in the determination of blood PCO2. Am Rev Respir Dis 1977; 115:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/11\">",
"      Williams AJ. ABC of oxygen: assessing and interpreting arterial blood gases and acid-base balance. BMJ 1998; 317:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/12\">",
"      Mueller RG, Lang GE, Beam JM. Bubbles in samples for blood gas determinations. A potential source of error. Am J Clin Pathol 1976; 65:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/13\">",
"      Hess CE, Nichols AB, Hunt WB, Suratt PM. Pseudohypoxemia secondary to leukemia and thrombocytosis. N Engl J Med 1979; 301:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/14\">",
"      Shapiro BA. Temperature correction of blood gas values. Respir Care Clin N Am 1995; 1:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/15\">",
"      Hansen JE. Arterial blood gases. Clin Chest Med 1989; 10:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/16\">",
"      Bacher A. Effects of body temperature on blood gases. Intensive Care Med 2005; 31:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/17\">",
"      Ream AK, Reitz BA, Silverberg G. Temperature correction of PCO2 and pH in estimating acid-base status: an example of the emperor's new clothes? Anesthesiology 1982; 56:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/18\">",
"      Weil MH, Rackow EC, Trevino R, et al. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. N Engl J Med 1986; 315:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/19\">",
"      Adrogu&eacute; HJ, Rashad MN, Gorin AB, et al. Assessing acid-base status in circulatory failure. Differences between arterial and central venous blood. N Engl J Med 1989; 320:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15894/abstract/20\">",
"      Mathias DW, Clifford PS, Klopfenstein HS. Mixed venous blood gases are superior to arterial blood gases in assessing acid-base status and oxygenation during acute cardiac tamponade in dogs. J Clin Invest 1988; 82:833.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1648 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15894=[""].join("\n");
var outline_f15_33_15894=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ARTERIAL SAMPLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Needle puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Site selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Collateral circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Indwelling catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPECIMEN CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TRANSPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28435429\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28435458\">",
"      Misleading results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1648\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1648|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/1/10260\" title=\"figure 1\">",
"      Anatomy of the radial artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/17/8464\" title=\"figure 2\">",
"      Radial artery puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/44/35533\" title=\"figure 3\">",
"      Brachial artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/19/3390\" title=\"figure 4\">",
"      Brachial artery puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/15/15600\" title=\"figure 5\">",
"      Femoral artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/51/38704\" title=\"figure 6\">",
"      Femoral artery puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/43/39604\" title=\"figure 7\">",
"      Anatomy of dorsalis pedis artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/58/10150\" title=\"figure 8\">",
"      Axillary artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/13/34014\" title=\"figure 9\">",
"      Axillary artery puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/61/4049\" title=\"figure 10\">",
"      Modified Allen test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/37/1616\" title=\"figure 11\">",
"      Dorsalis pedis artery puncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1648|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/52/40771\" title=\"picture 1\">",
"      The Allen test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1648|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/45/5852\" title=\"table 1\">",
"      Temperature and blood gas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3781?source=related_link\">",
"      Causes of lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=related_link\">",
"      Venous blood gases and other alternatives to arterial blood gases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_33_15895="Bleomycin: Pediatric drug information";
var content_f15_33_15895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bleomycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"    see \"Bleomycin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/49/26388?source=see_link\">",
"    see \"Bleomycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Blenoxane&reg;;",
"     </li>",
"     <li>",
"      Bleomycin Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antibiotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"      see \"Bleomycin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The risk for pulmonary toxicity increases with cumulative lifetime dose &gt;400 units; 1 unit = 1 mg. Details concerning dosage in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Test dose for lymphoma:",
"     </b>",
"     Children and Adolescents: I.V., SubQ: Because of the possibility of an anaphylactoid reaction, the manufacturer recommends administering 1-2 units of bleomycin before the first 1-2 doses; monitor vital signs every 15 minutes; wait a minimum of 1 hour before administering remainder of dose; if no acute reaction occurs, then the regular dosage schedule may be followed.",
"     <b>",
"      Note:",
"     </b>",
"     Test doses may not be predictive of a reaction (Lam, 2005) and/or may produce false-negative results.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hodgkin's lymphoma (combination regimen):",
"     </b>",
"     ABVD regimen: I.V.: 10 units/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 15 of a 28-day treatment cycle (Hutchinson, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Malignant germ cell cancer (combination therapy)",
"     </b>",
"     (Cushing, 2004): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants: 0.5",
"     <b>",
"      mg",
"     </b>",
"     /kg/dose day 1 of a 21-day treatment cycle for 4 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents: 15 units/m",
"     <sup>",
"      2",
"     </sup>",
"     day 1 of a 21-day treatment cycle for 4 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Test dose for lymphoma:",
"     </b>",
"     I.V., SubQ: Because of the possibility of an anaphylactoid reaction, the manufacturer recommends administering 1-2 units of bleomycin before the first 1-2 doses; monitor vital signs every 15 minutes; wait a minimum of 1 hour before administering remainder of dose; if no acute reaction occurs, then the regular dosage schedule may be followed.",
"     <b>",
"      Note:",
"     </b>",
"     Test doses may not be predictive of a reaction (Lam, 2005) and/or may produce false-negative results.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hodgkin's lymphoma (combination regimens):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ABVD: 10 units/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 15 of a 28-day treatment cycle (Straus, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     BEACOPP: 10 units/m",
"     <sup>",
"      2",
"     </sup>",
"     day 8 of a 21-day treatment cycle (Dann, 2007; Diehl, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stanford V: 5 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose in weeks 2, 4, 6, 8, 10, and 12 (Horning, 2000; Horning, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Malignant pleural effusion:",
"     </b>",
"     Intrapleural: 60 units as a single instillation; mix in 50-100 mL of NS and instill into the pleural cavity via a thoracostomy tube",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in obesity:",
"     </b>",
"     Adults: Fixed doses (dosing which is independent of body weight or BSA) are used in some protocols (eg, testicular cancer); due to toxicity concerns, the same fixed dose should also be considered for obese patients (Griggs, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer's labeling:",
"     <b>",
"      Note:",
"     </b>",
"     Creatinine clearance should be estimated using the Cockcroft-Gault formula:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-50 mL/minute: Administer 70% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-40 mL/minute: Administer 60% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-30 mL/minute: Administer 55% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-20 mL/minute: Administer 45% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-10 mL/minute: Administer 40% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Aronoff, 2007: Continuous renal replacement therapy (CRRT): Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 70% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 60% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Consider use of alternative drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); however, adjustment for hepatic impairment is not necessary (King, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmonary changes: Discontinue until determined not to be drug-related.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmonary diffusion capacity for carbon monoxide (DL",
"     <sub>",
"      CO",
"     </sub>",
"     ) &lt;30% to 35% of baseline: Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 15 units, 30 units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: May cause pain at injection site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Reconstitute 15-unit vial with 5 mL NS and the 30-unit vial with 10 mL NS. Administer I.V. slowly over at least 10 minutes at a concentration not to exceed 3 units/mL; bleomycin for continuous I.V. infusion can be further diluted in NS; administration by continuous infusion may produce less severe pulmonary toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: Reconstitute 15-unit vial with NS or sterile or bacteriostatic water for injection; 15 units/mL concentration may be used for administration; may cause pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrapleural: 60 units in 50-100 mL NS; use of topical anesthetics or narcotic analgesia is usually not necessary. Use appropriate precautions for handling and disposal.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F141895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, aztreonam, cefepime, cisplatin, cyclophosphamide, doxorubicin, doxorubicin liposome, droperidol, etoposide phosphate, filgrastim, fludarabine, fluorouracil, furosemide, gemcitabine, granisetron, heparin, leucovorin calcium, melphalan, methotrexate, metoclopramide, mitomycin, ondansetron, paclitaxel, piperacillin/tazobactam, sargramostim, teniposide, thiotepa, vinblastine, vincristine, vinorelbine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Cisplatin, cyclophosphamide, doxorubicin, droperidol, fluorouracil, furosemide, heparin, leucovorin calcium, methotrexate, metoclopramide, mitomycin, vinblastine, vincristine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); intact vials are stable 4 weeks at room temperature; solutions reconstituted in NS are stable for up to 28 days refrigerated and 14 days at room temperature; however, the manufacturer recommends stability of 24 hours in NS at room temperature. Incompatible when admixed with amino acid solutions, ascorbic acid, cefazolin, furosemide, diazepam, hydrocortisone, mitomycin, nafcillin, penicillin G, aminophylline, copper; dilution in dextrose solutions may result in a 10% loss of activity within 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of squamous cell carcinoma (of the head and neck, penis, cervix, or vulva), testicular carcinoma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma; sclerosing agent to control malignant effusions (FDA approved in adults); has also been used in the treatment of germ cell tumors and pediatric Hodgkin's lymphoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F141898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bleomycin may be confused with Cleocin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F141894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic:  Diffuse scleroderma, erythema, hyperkeratosis, induration, onycholysis, pain at the tumor site, phlebitis, pruritus, rash, skin thickening, striae, vesiculation; peeling of the skin (particularly on the palmar and plantar surfaces of the hands and feet); hyperpigmentation, alopecia, nailbed changes may also occur (appear dose related and reversible with discontinuation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, stomatitis and mucositis, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Death, hypoxia, Interstitial pneumonitis (acute or chronic), pulmonary fibrosis, rales, tachypnea; symptoms include cough, dyspnea, and bilateral pulmonary infiltrates. The pathogenesis is not certain, but may be due to damage of pulmonary, vascular, or connective tissue. Response to steroid therapy is variable and somewhat controversial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Acute febrile reactions; anaphylactoid-like reactions (characterized by hypotension, confusion, fever, chills, and wheezing; onset may be immediate or delayed for several hours); idiosyncratic reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Angioedema, cerebrovascular accident, cerebral arteritis, chest pain, coronary artery disease, flagellate hyperpigmentation, hepatotoxicity, malaise, MI, myelosuppression (rare), myocardial ischemia, nausea, pericarditis, Raynaud&rsquo;s phenomenon, renal toxicity, scleroderma-like skin changes, Stevens-Johnson syndrome, thrombotic microangiopathy, toxic epidermal necrolysis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bleomycin sulfate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution when administering O",
"     <sub>",
"      2",
"     </sub>",
"     during surgery to patients who have received bleomycin; the risk of bleomycin-related pulmonary toxicity is increased. Use caution with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); may require dose adjustment; may cause renal or hepatic toxicity. Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Occurrence of pulmonary fibrosis (commonly presenting as pneumonitis; occasionally progressing to pulmonary fibrosis) is the most severe toxicity; risk is higher in elderly patients and patients receiving &gt;400 units total lifetime dose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; but has also been reported in younger patients on low doses. Other possible risk factors include smoking and patients with prior radiation therapy or receiving concurrent oxygen (especially high-inspired oxygen doses). A review of patients receiving bleomycin for the treatment of germ cell tumors suggests risk for pulmonary toxicity is increased in patients &gt;40 years of age, with glomerular filtration rate &lt;80 mL/minute, advanced disease, and cumulative doses &gt;300 units (O&rsquo;Sullivan, 2003). Pulmonary toxicity may include bronchiolitis obliterans and organizing pneumonia (BOOP), eosinophilic hypersensitivity, and interstitial pneumonitis, progressing to pulmonary fibrosis (Sleijfer, 2001); pulmonary toxicity may be due to a lack of the enzyme which inactivates bleomycin (bleomycin hydrolase) in the lungs (Morgan, 2011; Sleijfer, 2001). If pulmonary changes occur, withhold treatment and investigate if drug-related. In children a younger age at treatment, cumulative dose &ge;400 units/m",
"     <sup>",
"      2",
"     </sup>",
"     (combined with chest irradiation) and renal impairment are associated with a higher incidence of pulmonary toxicity (Huang, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing (similar to anaphylaxis) has been reported in 1% of lymphoma patients treated with bleomycin",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Since these reactions usually occur after the first or second dose, careful monitoring is essential after these doses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Filgrastim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemcitabine: May enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sargramostim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F141819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3013953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal studies have demonstrated teratogenic and abortifacient effects. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulmonary function tests, including total lung volume, forced vital capacity, diffusion capacity for carbon monoxide; vital capacity, total lung capacity, and pulmonary capillary blood volume may be better indicators of changes induced by bleomycin (Sleifjer, 2001), chest x-ray; renal function, hepatic function, vital signs, and temperature initially; CBC with differential and platelet count; check body weight at regular intervals",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits synthesis of DNA; binds to DNA leading to single- and double-strand breaks by a Fe",
"     <sup>",
"      ++",
"     </sup>",
"     -O",
"     <sub>",
"      2",
"     </sub>",
"     -catalyzed free radical reaction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M. and intrapleural administration: 30% to 50% of I.V. serum concentrations; intraperitoneal and SubQ routes produce serum concentrations equal to those of I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 22 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; highest concentrations in skin, kidney, lung, and heart tissues; lowest in testes and GI tract; does not cross blood-brain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via several tissues, including hepatic, GI tract, skin, pulmonary, renal, and serum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic (renal function dependent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2.1-3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Normal renal function: Initial: 1.3 hours; Terminal: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     End-stage renal disease: Initial: 2 hours; Terminal: 30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (50% to 70% as active drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/49/26388?source=see_link\">",
"      see \"Bleomycin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This medication can only be administered by injection or infusion; report immediately any redness, burning, pain, or swelling at injection/infusion site. May cause loss of appetite, nausea, or vomiting; mouth sores; fever or chills (will usually resolve); rash, redness, peeling, or increased color of skin; or loss of hair (reversible after cessation of therapy). Report any change in respiratory status; respiratory difficulty; wheezing; air hunger; increased secretions; difficulty expectorating secretions; confusion; unresolved fever or chills; sores in mouth; vaginal itching, burning, or discharge; sudden onset of dizziness; acute headache; or burning, stinging, redness, or swelling at injection site.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carver JR, Shapiro CL, Ng A, et al, &ldquo;American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(25):3991-4008.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/17577017/pubmed\" id=\"17577017\" target=\"_blank\">",
"        17577017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cushing B, Giller R, Cullen JW, et al, \"Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study &minus; Pediatric Oncology Group 9049 and Children's Cancer Group 8882,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(13):2691-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/15226336/pubmed\" id=\"15226336\" target=\"_blank\">",
"        15226336",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dann EJ, Bar-Shalom R, Tamir A, et al, \"Risk-Adapted BEACOPP Regimen Can Reduce the Cumulative Dose of Chemotherapy for Standard and High-Risk Hodgkin Lymphoma With No Impairment of Outcome,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(3):905-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/17018856/pubmed\" id=\"17018856\" target=\"_blank\">",
"        17018856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diehl V, Franklin J, Pfreundschuh M, et al, \"Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(24):2386-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/12802024/pubmed\" id=\"12802024\" target=\"_blank\">",
"        12802024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engert A, Franklin J, Eich HT, et al, \"Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(23):3495-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/17606976/pubmed\" id=\"17606976\" target=\"_blank\">",
"        17606976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(13):1553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/22473167/pubmed\" id=\"22473167\" target=\"_blank\">",
"        22473167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Hoppe RT, Breslin S, et al, \"Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(3):630-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/11821442/pubmed\" id=\"11821442\" target=\"_blank\">",
"        11821442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Williams J, Bartlett NL, et al, \"Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(5):972-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/10694546/pubmed\" id=\"10694546\" target=\"_blank\">",
"        10694546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoskin PJ, Lowry L, Horwich A, et al, \"Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5390-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/19738111/pubmed\" id=\"19738111\" target=\"_blank\">",
"        19738111",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huang TT, Hudson MM, Stokes DC, et al, &ldquo;Pulmonary Outcomes in Survivors of Childhood Cancer: A Systematic Review,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2011, 140(4): 881-901.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/21415131/pubmed\" id=\"21415131\" target=\"_blank\">",
"        21415131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutchinson RJ, Fryer CJ, Davis PC, et al, \"MOPP or Radiation in Addition to ABVD in the Treatment of Pathologically Staged Advanced Hodgkin's Disease in Children: Results of the Children's Cancer Group Phase III Trial,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(3):897-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/9508171/pubmed\" id=\"9508171\" target=\"_blank\">",
"        9508171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ibrahimi OA and Anderson RR, \"Images in Clinical Medicine. Bleomycin-Induced Flagellate Hyperpigmentation,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(24):e36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/21142531/pubmed\" id=\"21142531\" target=\"_blank\">",
"        21142531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson PW, Radford JA, Cullen MH, et al, \"Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519),\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(36):9208-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/16314615/pubmed\" id=\"16314615\" target=\"_blank\">",
"        16314615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2001, 6(2):162-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/11306728/pubmed\" id=\"11306728\" target=\"_blank\">",
"        11306728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kung FH, Schwartz CL, Ferree CR, et al, \"POG 8625: A Randomized Trial Comparing Chemotherapy With Chemoradiotherapy for Children and Adolescents With Stages I, IIA, IIIA1 Hodgkin Disease: A Report From the Children's Oncology Group,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2006, 28(6):362-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/16794504/pubmed\" id=\"16794504\" target=\"_blank\">",
"        16794504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam MS, \"The Need for Routine Bleomycin Test Dosing in the 21st Century,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(11):1897-902.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/16219896/pubmed\" id=\"16219896\" target=\"_blank\">",
"        16219896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), \"Clinical Practice Guidelines in Oncology&trade;: Head and Neck Cancers,\" Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Straus DJ, Portlock CS, Qin J, et al, \"Results of a Prospective Randomized Clinical Trial of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Followed by Radiation Therapy (RT) Versus ABVD Alone for Stages I, II, and IIIA Nonbulky Hodgkin Disease,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 104(12):3483-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/33/15895/abstract-text/15315964/pubmed\" id=\"15315964\" target=\"_blank\">",
"        15315964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13088 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15895=[""].join("\n");
var outline_f15_33_15895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708640\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141845\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045592\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045584\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141823\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141808\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045596\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141895\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045587\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045595\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141898\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141894\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045599\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045583\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045582\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298875\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141817\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141819\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013953\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045591\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045581\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045598\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045589\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13088|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=related_link\">",
"      Bleomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/49/26388?source=related_link\">",
"      Bleomycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_33_15896="Graf hip types";
var content_f15_33_15896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Overview of the Graf hip classification types",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Donaldson, JS, Feinstein, KA. Imaging of developmental dysplasia of the hip. Pediatr Clin North Am 1997; 44:591.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15896=[""].join("\n");
var outline_f15_33_15896=null;
var title_f15_33_15897="Causes of wide QRS complex tachycardia in children";
var content_f15_33_15897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of wide QRS complex tachycardia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/33/15897/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15897/contributors\">",
"     Susan P Etheridge, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/33/15897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15897/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/33/15897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15897/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/33/15897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia in children is generally defined as a heart rate exceeding 120 beats per minute in older children and adolescents, and 180 beats per minute in infants and young children. The key to effective management of tachycardia is identifying its site of origin and understanding the underlying mechanism.",
"   </p>",
"   <p>",
"    Thus, one of the initial steps in the evaluation of a child with tachycardia includes examination of the standard electrocardiogram (ECG), because assessing the width of the QRS complex aids in determining the origin of the arrhythmia and guides management decisions (",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Narrow QRS complex tachycardia &mdash; A narrow QRS complex (QRS duration &le;80 msec) indicates that the origin of the arrhythmia is above or within the atrioventricular (AV) node. The short QRS duration indicates rapid activation of the ventricles through the AV node and the His-Purkinje system, and eliminates ventricular tachycardia (VT) as an etiology of the increased heart rate. Causes of narrow QRS complex tachycardia include sinus tachycardia, atrial fibrillation and flutter, and most cases of supraventricular tachycardia (SVT). These conditions are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=see_link\">",
"       \"Sinus tachycardia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=see_link\">",
"       \"Atrial flutter: Epidemiology, classification, and risk factors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wide QRS complex tachycardia &mdash; With wide QRS complex (QRS duration &gt;80 msec) tachycardia, VT must be first considered, because VT may rapidly degenerate to ventricular fibrillation and result in cardiac arrest. Wide QRS complex tachycardia may also be seen in patients with supraventricular tachycardia with an aberrant conduction system or antidromic AV reentrant tachycardia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supraventricular tachycardia'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H3\">",
"       'Ventricular tachycardia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Causes of wide QRS complex tachycardia in children will be reviewed here. The evaluation and management of wide QRS complex tachycardia in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=see_link\">",
"     \"Management and evaluation of wide QRS complex tachycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPRAVENTRICULAR TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraventricular tachycardia (SVT) originates above the ventricles, and usually presents as a narrow QRS complex tachycardia. However, SVT can also produce a wide QRS complex through the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aberrant conduction &mdash; Conduction through the His-Purkinje system can be delayed or blocked, which results in a wide QRS complex. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18308?source=see_link\">",
"       \"Basic approach to delayed intraventricular conduction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AV reentrant tachycardia (AVRT) with an accessory AV pathway &mdash; AVRT requires the presence of an extranodal accessory pathway connecting the atrium and ventricle. This allows direct electrical communication between the two chambers.",
"      <br/>",
"      <br/>",
"      During AVRT tachycardia, QRS complexes can be either narrow or wide depending upon the direction of conduction through the reentrant pathway. If the ventricles are activated antegradely via the accessory pathway followed by retrograde conduction over the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system, the QRS complex will be wide. This is known as antidromic AVRT (",
"      <a class=\"graphic graphic_waveform graphicRef54484 \" href=\"UTD.htm?24/55/25464\">",
"       waveform 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef71410 \" href=\"UTD.htm?43/2/44072\">",
"       waveform 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In the more common orthodromic form with a narrow QRS complex, the ventricles are activated antegradely through the AV node followed by retrograde conduction back to the atria via the accessory pathway.",
"      <br/>",
"      <br/>",
"      AV reentrant tachycardia is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link&amp;anchor=H7#H7\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Orthodromic versus antidromic'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link&amp;anchor=H2#H2\">",
"       \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\", section on 'Tachycardias requiring an AV accessory pathway for initiation and maintenance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VENTRICULAR TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia (VT) originates from the ventricular myocardium or Purkinje cells below the bifurcation of the bundle of His. It is reported to occur in 3 percent of healthy children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VT is associated with sudden cardiac death. As a result, patients who develop VT or are at risk for developing VT must be identified, evaluated, and treated if necessary. Some forms of VT found primarily in infants and young children may be benign, but this conclusion is reached only after other more serious causes of VT are excluded.",
"   </p>",
"   <p>",
"    VT is defined as three or more consecutive beats of ventricular origin on ECG. It can occur in patients with congenital heart disease, an inherited disorder that affects cardiac muscle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function, acquired heart disease, or in the setting of a structurally and functionally normal heart.",
"   </p>",
"   <p>",
"    In one retrospective review from a single Swiss center, 27 children with spontaneous episodes of VT were observed from 1995 to 2005; 13 had no structural heart disease, and the remaining 14 patients had a wide range of underlying cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/3\">",
"     3",
"    </a>",
"    ]. Five patients died, all of whom had underlying cardiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias, including VT, are often seen as a late complication in children and adults with congenital heart disease (CHD), and are associated with a significant increase in mortality and serious morbidity. The electronic pathophysiology in CHD is based upon a complex interplay between gross cardiac anatomy, chamber enlargement from abnormal pressure and volume loads, cellular injury from hypoxia and cardiopulmonary bypass, fibrosis at the site of suture lines, and direct trauma to the specialized conduction tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VT is most frequently associated with patients with tetralogy of Fallot, although it may occur in patients with other congenital defects (eg, transposition of the great arteries, Ebstein's anomaly, and lesions with left ventricular outflow obstruction) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. After surgical repair of tetralogy of Fallot, the incidences of VT and sudden cardiac death have been reported to be as high as 12 and 8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/9\">",
"     9",
"    </a>",
"    ]. The origin of VT is primarily at the site of surgical repair. Although less common, ventricular arrhythmias have been seen in patients with CHD who have not undergone intracardiac surgical repair, suggesting that surgical scar is not the only cause for VT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/4,10\">",
"     4,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In individuals with tetralogy of Fallot, the presence of residual cardiac defects, volume overload, or cardiac dysfunction has been associated with an increase risk of VT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/11\">",
"     11",
"    </a>",
"    ]. In adults, left ventricular failure has been associated with sudden death following surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/12\">",
"     12",
"    </a>",
"    ]. Several studies have also reported that postoperative patients with a QRS duration that is greater than or equal to 180 msec were more likely to develop VT or sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Other reported risk factors for VT following surgical repair for tetralogy of Fallot include older age at repair and increased length of time from repair [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/12\">",
"     12",
"    </a>",
"    ], a history of palliative shunts, inducible VT at electrophysiology (EP) testing, and high grade ventricular ectopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/4\">",
"     4",
"    </a>",
"    ]. Age at repair seems to correlate with the development of left ventricular dysfunction possibly due to prolonged periods of time with volume overload and hypoxia.",
"   </p>",
"   <p>",
"    Although patients may experience slow VT and are hemodynamically stable at presentation, some patients present with rapid VT that results in syncope or cardiac arrest. VT is the most common cause of sudden death in patients following surgical repair for tetralogy of Fallot; however, atrial arrhythmias and AV block may also have catastrophic outcomes in adults with CHD, including death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EP testing with programmed ventricular stimulation is useful in identifying postoperative patients with CHD who are at increased risk of developing serious arrhythmias including VT. This was illustrated in a study of 252 postoperative patients with tetralogy of Fallot (mean age 16 years) who had programmed ventricular stimulation at the time of EP testing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/8\">",
"     8",
"    </a>",
"    ]. Sustained monomorphic VT was induced in 30 percent and polymorphic VT in 4.4 percent of patients. There was a threefold increase in the incidence of symptomatic VT or sudden death in patients with a positive EP study compared to those with a negative test. Thus, the induction of VT at EP testing is an imperfect but powerful predictor, independent of ECG and other clinical variables [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among pediatric cardiologists, there is general consensus that patients with sustained VT and symptoms require treatment. However, opinions vary upon the management of patients who are asymptomatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with ectopy upon routine surveillance monitoring or testing.",
"   </p>",
"   <p>",
"    Comprehensive treatment of VT in congenital heart diseases includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Correction of residual hemodynamic defects",
"     </li>",
"     <li>",
"      Arrhythmia management, which includes drug therapy, ablation either by catheter or surgery,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      placement of an implantable cardioverter-defibrillator (ICD)",
"     </li>",
"     <li>",
"      In some cases, medications are often inadequate, and many centers advocate catheter ablation or ICD implantation. In several studies, radiofrequency catheter ablation has been successful in treating ventricular arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/16-20\">",
"       16-20",
"      </a>",
"      ]. Hemodynamically stable VT and inducible monomorphic VT may be successfully mapped and be amenable to catheter ablation. Although ablation may decrease the risk of subsequent VT in patients with inducible monomorphic VT, recurrences are common, and ablation has not been shown to reduce the risk of sudden death. In a large case series of 97 patients with CHD, the overall success rate of ablation based upon an \"intention-to-treat\" analysis was 61 percent. In addition, in a small case report, successful ablation using three-dimensional substrate mapping during sinus rhythm was reported in 11 patients with VT after repair of CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/19\">",
"       19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although antiarrhythmic agents may be of benefit, ICD implantation is required in any patient presenting with a cardiac arrest. The decision to implant an ICD for other indications is less clear.",
"     </li>",
"     <li>",
"      Biventricular pacing has an emerging role in preserving ventricular function in the CHD population with decreased systemic ventricular function [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Although the application of this technology in adult heart failure has fairly clearly defined indications, the heterogeneity of the population has made establishing definitive guidelines difficult in CHD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our center, in addition to a presentation with cardiac arrest or sustained hemodynamically unstable VT, the following are considerations when evaluating a patient with CHD for ICD implantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      24-hour Holter monitor documentation of nonsustained VT or significant polymorphic ventricular ectopy, even in asymptomatic patients",
"     </li>",
"     <li>",
"      Evidence on electrocardiogram (ECG) of prolonged QRS duration",
"     </li>",
"     <li>",
"      History of multiple surgical interventions",
"     </li>",
"     <li>",
"      Inducible VT during EP testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;With molecular genetic advances, several genetic disorders that are associated with VT have been identified. They can be classified as channelopathies or cardiomyopathic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Channelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited channelopathies associated with VT are briefly reviewed here and are discussed individually in detail separately. These disorders affect the movement of ions (eg, sodium, potassium, and calcium) through channels within the cardiac cell membrane and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long QT syndrome &mdash; The long QT syndrome (LQTS) is a disorder of myocardial repolarization characterized by a prolonged QT interval and T wave abnormalities on the ECG, syncope, and sudden cardiac death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Although mutations in a number of cardiac ion genes and genes that affect ion channel function have been identified in patients with congenital LQTS (",
"      <a class=\"graphic graphic_table graphicRef58151 \" href=\"UTD.htm?31/27/32189\">",
"       table 1",
"      </a>",
"      ), most patients have a loss of function of a potassium channel (eg, KCNQ1 and KCNH2) or a gain of function of a sodium channel (eg, SCN5A).",
"     </li>",
"     <li>",
"      The clinical phenotypes of congenital LQTS include the common autosomal dominant form, the Romano-Ward syndrome, which has a purely cardiac phenotype. The autosomal recessive form, the Jervell and Lange-Nielsen syndrome, is associated with LQTS and sensorineural deafness, and has a more malignant clinical course. Other rare forms of LQTS include Timothy syndrome (characterized by profound QT prolongation, structural cardiac disease, and noncardiac manifestations) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/24\">",
"       24",
"      </a>",
"      ] and Andersen-Tawil syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/25\">",
"       25",
"      </a>",
"      ]. In Andersen-Tawil syndrome, some patients will have LQTS (LQTS 7) and other cardiac electrophysiologic abnormalities (eg, mild QTc prolongation, a prominent U wave on the ECG, and very high burden of ventricular arrhythmias, specifically bidirectional ventricular ectopy and tachycardia) and noncardiac findings (eg, weakness or periodic paralysis and dysmorphic features).",
"     </li>",
"     <li>",
"      LQTS is associated with an increased risk of life-threatening arrhythmias referred to as torsades de pointes (",
"      <a class=\"graphic graphic_waveform graphicRef73827 \" href=\"UTD.htm?42/7/43134\">",
"       waveform 3",
"      </a>",
"      ). Causes of acquired prolonged QTc duration (eg, drugs, hypokalemia, and hypomagnesemia) can also precipitate ventricular arrhythmia in patients with congenital LQTS. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Acquired heart disease'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with LQTS present with syncope, seizures, or cardiac arrest. A family history of sudden death, seizures, recurrent syncope, or unexplained drowning should heighten the suspicion of LQTS. Data show a link between LQTS and 5 to 10 percent of cases of sudden infant death syndrome. There are growing data that LQTS may present in utero with ventricular arrhythmias, AV block, and sinus bradycardia and may be associated with early fetal demise [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical features of congenital long QT syndrome\", section on 'Associated conditions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The mortality rate in LQTS is reduced with earlier identification of affected patients and treatment, including beta blocker therapy, sports restriction in some, and avoidance of medications known to lengthen the QTc interval. High-risk patients including those with persistent symptoms despite beta blocker therapy may benefit from ICD implantation or left cardiac sympathetic denervation. The strict sports restrictions previously applied to all patients with LQTS should be tailored to the patient and to",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      genotypic and phenotypic expression of the disease. Physical exertion (particularly swimming) appears to be a common trigger for ventricular arrhythmias in LQT1, whereas individuals with LQT2 seem more at-risk to auditory or emotional triggers and whereas patients with LQT3 may be at greater risk during rest and in activity. However, exceptions to these genotype-phenotype correlations hinder genotype-specific tailoring of competitive sports recommendations. The entire personal and family phenotype must be incorporated before any eligibility or disqualification decision is rendered [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/27\">",
"       27",
"      </a>",
"      ]",
"      <br/>",
"      <br/>",
"      The clinical features, diagnosis, genetic defects, and management of LQTS are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"       \"Clinical features of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link\">",
"       \"Diagnosis of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"       \"Genetics of congenital and acquired long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link\">",
"       \"Prognosis and management of congenital long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brugada syndrome &mdash; Brugada syndrome, first described in 1992 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/28\">",
"       28",
"      </a>",
"      ], is an uncommon channelopathy. Brugada syndrome is associated with characteristic ECG findings of ST segment elevation in leads V1 to V3 and a right bundle branch block pattern in the right precordial leads (",
"      <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"UTD.htm?8/35/8762\">",
"       waveform 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Brugada syndrome is inherited in an autosomal dominant pattern with variable expression. Gene mutations of SCN5A, which encodes for the subunit of a cardiac sodium channel, resulting in a loss of sodium channel function has been found in 10 to 30 percent of patients with Brugada syndrome. In contrast, patients with congenital LQTS have SCN5A mutations that results in a gain in sodium channel function. Genetic mutations, other than SCN5A mutations, may also produce the phenotypic characteristics of Brugada syndrome.",
"      <br/>",
"      <br/>",
"      Affected patients present with life-threatening ventricular arrhythmias. Sudden cardiac death may be the first and only clinical event in Brugada syndrome, occurring in as many as one-third of patients. Death usually occurs during sleep and in the early morning hours. A family history of sudden death at a young age is commonly found. In some patients, the typical ECG findings of Brugada are present intermittently but may be unmasked by fever or the administration of medications.",
"      <br/>",
"      <br/>",
"      The clinical features, diagnosis, and management of Brugada syndrome are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Catecholaminergic polymorphic ventricular tachycardia &mdash; Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for VT (specifically bidirectional VT), ventricular fibrillation, and sudden death, especially in association with stress or exercise (",
"      <a class=\"graphic graphic_waveform graphicRef76976 \" href=\"UTD.htm?19/49/20249\">",
"       waveform 5",
"      </a>",
"      ). Like LQT1, there are increasing data to suggest that some drowning and near drowning events and SIDS are associated with CPVT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      At rest, the ECG typically demonstrates frequent premature ventricular contractions (PVC) and nonsustained polymorphic VT. The QT interval is normal, which distinguishes it from LQTS, and there are no ST segment changes differentiating it from Brugada syndrome.",
"      <br/>",
"      <br/>",
"      This disorder is inherited in an autosomal dominant or autosomal recessive pattern, and also occurs in sporadic cases as a de novo mutation. Various mutations of gene loci that encode proteins involved in calcium regulation across the sarcoplasmic reticulum have been identified in patients with CPVT. These include mutations of the RyR2 gene (which encodes the human cardiac ryanodine receptor) and the calsequestrin 2 gene (which encodes a major calcium reservoir protein within the sarcoplasmic reticulum). In a large affected Swedish family, a mutation in the CALM 1 gene, which encodes calmodulin, was identified and resulted in compromised calcium binding [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"      CPVT is a disease of childhood, as it rarely presents in infancy and is less common in adults. One possible explanation for the increased prevalence during childhood is the intensity of exercise is more limited in infants and the more sedentary adult population, resulting in fewer affected patients in these age groups. Approximately 30 percent of patients have a family history of sudden death, often in adolescence. Prognosis is guarded, even in patients in whom the disease is identified and treatment instituted. At present, therapies include beta blockers,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/49/32534?source=see_link\">",
"       flecainide",
"      </a>",
"      , and ICD or left cardiac sympathetic denervation for high risk patients and those with symptoms despite beta blocker therapy. These therapies and the clinical features of CPVT are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H3#H3\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Catecholaminergic polymorphic VT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;VT can often be associated with inherited cardiomyopathic disorders and, less commonly, with more generalized inherited myopathic diseases, such as myotonic dystrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link&amp;anchor=H10#H10\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\", section on 'Conduction disturbances'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a brief review of the inherited cardiomyopathies associated with ventricular arrhythmias, which are discussed in greater detail separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertrophic cardiomyopathy &mdash; Hypertrophic cardiomyopathy remains the most common cause of sudden death in young people in the United States. It is a genetic disease of the cardiac sarcomere that is caused by mutations in one of more than 50 genes that encode most, if not all of the myocardial contractile proteins. This leads to wide variation in the clinical presentation and course of this disorder, and makes standardization of therapy difficult.",
"      <br/>",
"      <br/>",
"      Genetic testing, clinical manifestations, and treatment of patients with hypertrophic cardiomyopathy are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"       \"Genetics of hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"       \"Natural history of hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"       \"Medical therapy in hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients with hypertrophic cardiomyopathy, ventricular arrhythmias are thought to be due to electrically unstable myocardium resulting from myocellular disarray, fibrosis, and ischemia. Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"       \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy &mdash; Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disorder of the right ventricle characterized by fatty or fibrofatty replacement of the myocardium resulting in myocardial thinning, aneurysm formation, and wall motion abnormalities. In some cases, there may also be left ventricle involvement with relative sparring of the ventricular septum.",
"      <br/>",
"      <br/>",
"      ARVC was thought to be rare, but is now thought to account for 3 to 5 percent of unexplained sudden deaths in adolescents and young adults, and up to 11 percent in northern Italy. Both autosomal dominant and recessive forms of ARVC have been reported with identified mutations in several desmosomal protein genes. Autosomal recessive ARVC is less common and can be part of a syndrome called Naxos disease, which also includes hyperkeratosis of the palms and soles, and wooly hair. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=see_link&amp;anchor=H6#H6\">",
"       \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Genetics'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Affected patients generally present between 10 and 50 years of age with dizziness, palpitations, and syncope due to VT. The VT has a left bundle branch pattern that should lead one to consider a right ventricular origin. Other ECG findings of ARVC, the clinical findings, diagnostic evaluation, and treatment of ARVC are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"       \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Duchenne muscular dystrophy (DMD) &mdash; With improved management, patients with Duchenne muscular dystrophy are surviving into their 20s, and cardiomyopathy is emerging as a cause of morbidity and mortality. Heart failure and associated fibrosis in patients with DMD predisposes patients to ventricular arrhythmias, which is associated with a risk of sudden cardiac death [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Barth Syndrome is an x-linked disorder characterized by a dilated cardiomyopathy, cyclic neutropenia, skeletal myopathy, and growth delay. Ventricular arrhythmias and sudden death can occur in this population, and monitoring for this should be undertaken in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acquired heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired heart diseases that can result in VT in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary heart disease &mdash; Unlike adults, VT is rarely caused by coronary heart disease in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"       \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myocarditis &mdash; Viral infections of the myocardium may be associated with ventricular ectopy and complex ventricular tachycardia and heart failure. Some cardiologists recommend endomyocardial biopsies in patients with unexplained ventricular tachycardia. The clinical manifestations, diagnosis, and treatment of myocarditis are found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chagas disease is caused by the parasite Trypanosoma cruzi, which resides primarily in Central and South America. Although uncommon in children, dilated cardiomyopathy can develop and is associated with heart block and VT during the chronic phase of the infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and diagnosis of Chagas heart disease\", section on 'Arrhythmias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acquired QTc prolongation &mdash; Like congenital long QT syndrome (LQTS), patients with acquired QTc prolongation are at risk for developing polymorphic VT. QTc prolongation can be caused by the following:",
"     </li>",
"     <li>",
"      Metabolic disturbances: Hypokalemia, hypomagnesemia, or anorexia nervosa (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link&amp;anchor=H31379357#H31379357\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Cardiovascular'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Myocardial infarction or ischemia",
"     </li>",
"     <li>",
"      Intracranial disease: Stroke",
"     </li>",
"     <li>",
"      Drugs: Antiarrhythmic drugs (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=see_link\">",
"       quinidine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       procainamide",
"      </a>",
"      ), some nonsedating antihistamines (eg, terfenadine or astemizole), macrolide antibiotics, or antipsychotic and antidepressant medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rarely, VT may be caused to primary cardiac tumors. In a retrospective study from a tertiary center from 1968 to 2010, 173 children were identified with primary cardiac tumors (eg, fibroma [n = 25], myxoma [n = 14], teratoma [n = 4], lipoma [n = 3], and other masses [n = 15]) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/34\">",
"       34",
"      </a>",
"      ]. Of these, about a quarter had significant arrhythmias, VT being the most common abnormality. In particular, two-thirds of patients with fibromas had VT. Surgical excision was performed in 62 patients. Postoperatively, arrhythmias resolved in 18 or 20 patients, including 13 with fibromas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of acquired QTc prolongation are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Idiopathic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively benign forms of VT can be seen in children without demonstrable pathology. They include accelerated ventricular rhythm, right ventricular outflow tract tachycardia, and left ventricular tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Accelerated ventricular rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated ventricular rhythm is a relatively slow monomorphic VT. The rate tends to be just slightly above sinus rate, most often slower than 120 beats per minute, and usually not exceeding 200 beats per minute. Although most commonly seen in newborns, accelerated ventricular rhythm may be present in older children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accelerated ventricular rhythm is distinguished from other more malignant forms of VT because of its slower rate and the absence of symptoms. In addition, accelerated ventricular rhythm is usually suppressed by exertion, whereas VT from other causes may persist or degenerate into ventricular fibrillation during exercise. Accelerated ventricular rhythm is generally diagnosed only in patients with a structurally and functionally normal heart, although rare cases have been seen in children with congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ECG typically shows sinus rhythm followed by fusion beats at the onset of the ventricular rhythm and at its termination. The electrophysiologic mechanism is unknown and may include triggered activity or abnormal automaticity.",
"   </p>",
"   <p>",
"    Accelerated ventricular rhythm is a benign condition that often occurs in newborn infants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/38\">",
"     38",
"    </a>",
"    ]. It resolves spontaneously and should not be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, it is important to differentiate this rhythm disturbance from pathologic VT to avoid potentially toxic antiarrhythmic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Right ventricular outflow tract tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, idiopathic right ventricular outflow tract (RVOT) tachycardia is a benign condition that may resolve spontaneously. This rhythm disturbance is thought to be a cAMP-mediated triggered activity that arises from the RVOT. It is characterized by relatively slow rates (140 to 190 beats per minute) with a monomorphic QRS pattern of left bundle branch block and an inferior axis.",
"   </p>",
"   <p>",
"    Most children with RVOT are asymptomatic and present because of an incidental finding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/35\">",
"     35",
"    </a>",
"    ]. This was illustrated in a retrospective review of 48 Canadian children with RVOT tachycardia who presented at a median age of 8.2 years. Forty-one of the 48 patients (82 percent) presented with an incidental finding of an irregular heart rhythm or abnormal ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/35\">",
"     35",
"    </a>",
"    ]. Seven patients were referred because of syncope or near syncope. Reported symptoms obtained during from interviews of patients included abdominal pain, asthma-related complaints, fatigue, fever, limb pain, and rash.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) may reveal subtle abnormalities of the right ventricle, including thinning of the ventricular free wall, fatty infiltration, and wall motion abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/35\">",
"     35",
"    </a>",
"    ]. In the previously mentioned Canadian study, 13 of the 25 patients studied by MRI had abnormalities of the right ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major challenge for the clinician is to distinguish children with RVOT tachycardia from the more serious arrhythmogenic right ventricular cardiomyopathy (ARVC), discussed above, which has a high risk of sudden cardiac death. An incidental presentation and slow VT generally are more characteristic of patients with RVOT compared to those with ARVC. However, further diagnostic testing including MRI, electrophysiologic testing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signal-averaged ECG may further differentiate the two entities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H29#H29\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'RVOT tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment for RVOT tachycardia is indicated for symptomatic patients and those rare patients that develop tachycardia-induced cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/39\">",
"     39",
"    </a>",
"    ]. Therapy includes antiarrhythmic agents and catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/35\">",
"     35",
"    </a>",
"    ]. Catheter ablation has proven highly successful and the application of novel mapping systems, noncontact and electroanatomical techniques will likely further increase efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis for this condition is excellent. In the previously mentioned Canadian case series, there were no deaths, and 17 patients had resolution of ectopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VT can originate from the left ventricular outflow tract (LVOT), and is similar to RVOT tachycardia in its clinical manifestations, prognosis, and management. In patients with LVOT tachycardia, the ECG demonstrates monomorphic VT with a right bundle branch block and inferior axis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link&amp;anchor=H9#H9\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'Repetitive monomorphic VT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Idiopathic left ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic left ventricular tachycardia (also referred to as left ventricular fascicular tachycardia or Belhassen's tachycardia) is a benign VT. In affected patients, the ECG demonstrates a right bundle branch block with a superior or left axis.",
"   </p>",
"   <p>",
"    Idiopathic left ventricular tachycardia originates from the left posterior fascicle and occurs in the absence of structural disease, although it may be related to a false tendon that extends from the posteroinferior left ventricle to the septum.",
"   </p>",
"   <p>",
"    The mechanism of VT is thought to be reentry, as it is initiated with atrial and ventricular pacing. The VT is sensitive to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"     verapamil",
"    </a>",
"    . Although catheter ablation is an effective cure, even without therapy, this form of VT has a good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link&amp;anchor=H22#H22\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'Idiopathic left ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recent application of noncontact mapping strategies to both RVOT tachycardia and idiopathic left ventricular tachycardia has increased the ability to provide a cure for these problems in children, even when the tachycardia is not sustained [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15897/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia in children is generally defined as a heart rate exceeding 120 beats per minute in older children and adolescents, and 180 beats per minute in infants and young children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial steps in the evaluation of a child with tachycardia include examination of the standard electrocardiogram (ECG) and assessment of the duration of the QRS complex. If the QRS complex is greater than 80 msec, the patient has wide QRS complex tachycardia.",
"     </li>",
"     <li>",
"      In patients with wide QRS complex tachycardia, ventricular tachycardia (VT) must be first considered as the etiology because of the association with sudden cardiac death (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 1",
"      </a>",
"      ). As a result, patients who develop VT or are at risk for developing VT must be identified, evaluated, and treated if necessary. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ventricular tachycardia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=see_link\">",
"       \"Management and evaluation of wide QRS complex tachycardia in children\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      VT is often seen as a late surgical complication in patients with congenital heart disease. Management includes correction of residual hemodynamic defects and arrhythmia management. In general, patients who are symptomatic or have sustained VT receive therapy. However, there is no general consensus on whether or not asymptomatic patients should be treated. Treatment options include drug therapy, ablation either by catheter or surgery,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      placement of an implantable cardioverter-defibrillator (ICD).",
"     </li>",
"     <li>",
"      We recommend ICD implantation in individuals who have undergone surgical correction for congenital heart disease and suffer a cardiac arrest (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In our center, other considerations when contemplating ICD implantation include inducible VT during EP testing, QRS duration &gt;180 msec, and significant ectopy or VT on 24-hour Holter monitoring.",
"     </li>",
"     <li>",
"      VT is associated with inherited disorders that affect the cardiac muscle",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      function. These include channelopathies (eg, long QTS and Brugada syndromes, and familial catecholaminergic polymorphic ventricular tachycardia) and inherited causes of cardiomyopathy (eg, hypertrophic cardiomyopathy) that can present with life-threatening ventricular arrhythmias or a history of unexplained death in a young family member. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Genetic disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired heart diseases associated with VT include myocarditis and acquired QTc prolongation. Unlike adults, coronary artery disease is rarely a cause of VT in children. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Acquired heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic VT found primarily in infants and young children with structurally normal hearts may be benign, but this conclusion is reached only after other more serious causes of VT are excluded. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Idiopathic causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wide QRS complex tachycardia can be seen in patients with supraventricular tachycardia with an aberrant conduction systems or antidromic AV reentrant tachycardia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supraventricular tachycardia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/1\">",
"      Viitasalo MT, Kala R, Eisalo A. Ambulatory electrocardiographic recording in endurance athletes. Br Heart J 1982; 47:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/2\">",
"      Dickinson DF, Scott O. Ambulatory electrocardiographic monitoring in 100 healthy teenage boys. Br Heart J 1984; 51:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/3\">",
"      Roggen A, Pavlovic M, Pfammatter JP. Frequency of spontaneous ventricular tachycardia in a pediatric population. Am J Cardiol 2008; 101:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/4\">",
"      Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation 2007; 115:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/5\">",
"      Walsh EP, Rockenmacher S, Keane JF, et al. Late results in patients with tetralogy of Fallot repaired during infancy. Circulation 1988; 77:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/6\">",
"      Keane JF, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. Circulation 1993; 87:I16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/7\">",
"      Houyel L, Vaksmann G, Fournier A, Davignon A. Ventricular arrhythmias after correction of ventricular septal defects: importance of surgical approach. J Am Coll Cardiol 1990; 16:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/8\">",
"      Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation 2004; 109:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/9\">",
"      Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000; 356:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/10\">",
"      Deanfield JE, McKenna WJ, Presbitero P, et al. Ventricular arrhythmia in unrepaired and repaired tetralogy of Fallot. Relation to age, timing of repair, and haemodynamic status. Br Heart J 1984; 52:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/11\">",
"      Bricker JT. Sudden death and tetralogy of Fallot. Risks, markers, and causes. Circulation 1995; 92:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/12\">",
"      Ghai A, Silversides C, Harris L, et al. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. J Am Coll Cardiol 2002; 40:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/13\">",
"      Berul CI, Hill SL, Geggel RL, et al. Electrocardiographic markers of late sudden death risk in postoperative tetralogy of Fallot children. J Cardiovasc Electrophysiol 1997; 8:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/14\">",
"      Gatzoulis MA, Till JA, Redington AN. Depolarization-repolarization inhomogeneity after repair of tetralogy of Fallot. The substrate for malignant ventricular tachycardia? Circulation 1997; 95:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/15\">",
"      Khairy P, Marelli AJ. Clinical use of electrocardiography in adults with congenital heart disease. Circulation 2007; 116:2734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/16\">",
"      Papagiannis J, Kanter RJ, Wharton JM. Radiofrequency catheter ablation of multiple haemodynamically unstable ventricular tachycardias in a patient with surgically repaired tetralogy of Fallot. Cardiol Young 1998; 8:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/17\">",
"      Stevenson WG, Delacretaz E, Friedman PL, Ellison KE. Identification and ablation of macroreentrant ventricular tachycardia with the CARTO electroanatomical mapping system. Pacing Clin Electrophysiol 1998; 21:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/18\">",
"      Walsh EP. Arrhythmias in patients with congenital heart disease. Card Electrophysiol Rev 2002; 6:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/19\">",
"      Morwood JG, Triedman JK, Berul CI, et al. Radiofrequency catheter ablation of ventricular tachycardia in children and young adults with congenital heart disease. Heart Rhythm 2004; 1:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/20\">",
"      Laohakunakorn P, Paul T, Knick B, et al. Ventricular tachycardia in nonpostoperative pediatric patients: role of radiofrequency catheter ablation. Pediatr Cardiol 2003; 24:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/21\">",
"      Dubin AM, Janousek J, Rhee E, et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol 2005; 46:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/22\">",
"      Cecchin F, Frangini PA, Brown DW, et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: five years experience in a single institution. J Cardiovasc Electrophysiol 2009; 20:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/23\">",
"      van der Hulst AE, Delgado V, Blom NA, et al. Cardiac resynchronization therapy in paediatric and congenital heart disease patients. Eur Heart J 2011; 32:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/24\">",
"      Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/25\">",
"      Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001; 105:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/26\">",
"      Mitchell JL, Cuneo BF, Etheridge SP, et al. Fetal heart rate predictors of long QT syndrome. Circulation 2012; 126:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/27\">",
"      Zipes DP, Ackerman MJ, Estes NA 3rd, et al. Task Force 7: arrhythmias. J Am Coll Cardiol 2005; 45:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/28\">",
"      Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/29\">",
"      Tester DJ, Dura M, Carturan E, et al. A mechanism for sudden infant death syndrome (SIDS): stress-induced leak via ryanodine receptors. Heart Rhythm 2007; 4:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/30\">",
"      Nyegaard M, Overgaard MT, S&oslash;ndergaard MT, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet 2012; 91:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/31\">",
"      Chenard AA, Becane HM, Tertrain F, et al. Ventricular arrhythmia in Duchenne muscular dystrophy: prevalence, significance and prognosis. Neuromuscul Disord 1993; 3:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/32\">",
"      Connuck DM, Sleeper LA, Colan SD, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008; 155:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/33\">",
"      Spencer CT, Byrne BJ, Gewitz MH, et al. Ventricular arrhythmia in the X-linked cardiomyopathy Barth syndrome. Pediatr Cardiol 2005; 26:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/34\">",
"      Miyake CY, Del Nido PJ, Alexander ME, et al. Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia. J Am Coll Cardiol 2011; 58:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/35\">",
"      Harris KC, Potts JE, Fournier A, et al. Right ventricular outflow tract tachycardia in children. J Pediatr 2006; 149:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/36\">",
"      Davis AM, Gow RM, McCrindle BW, Hamilton RM. Clinical spectrum, therapeutic management, and follow-up of ventricular tachycardia in infants and young children. Am Heart J 1996; 131:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/37\">",
"      Reynolds JL, Pickoff AS. Accelerated ventricular rhythm in children: a review and report of a case with congenital heart disease. Pediatr Cardiol 2001; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/38\">",
"      Van Hare GF, Stanger P. Ventricular tachycardia and accelerated ventricular rhythm presenting in the first month of life. Am J Cardiol 1991; 67:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/39\">",
"      Paul T, Blaufox AT, Saul JP. Non-contact mapping and ablation of tachycardia originating in the right ventricular outflow tract. Cardiol Young 2002; 12:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/40\">",
"      Ohe T, Aihara N, Kamakura S, et al. Long-term outcome of verapamil-sensitive sustained left ventricular tachycardia in patients without structural heart disease. J Am Coll Cardiol 1995; 25:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15897/abstract/41\">",
"      Schneider HE, Kriebel T, Jung K, et al. Catheter ablation of idiopathic left and right ventricular tachycardias in the pediatric population using noncontact mapping. Heart Rhythm 2010; 7:731.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5786 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15897=[""].join("\n");
var outline_f15_33_15897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPRAVENTRICULAR TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VENTRICULAR TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Channelopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acquired heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Idiopathic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Accelerated ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Right ventricular outflow tract tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Idiopathic left ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5786\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5786|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 1\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5786|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/27/32189\" title=\"table 1\">",
"      Genetic abnormalities LQTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5786|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?24/55/25464\" title=\"waveform 1\">",
"      12 lead ECG antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/2/44072\" title=\"waveform 2\">",
"      ECG Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/7/43134\" title=\"waveform 3\">",
"      ECG torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/35/8762\" title=\"waveform 4\">",
"      ECG Brugada syndrome type I pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?19/49/20249\" title=\"waveform 5\">",
"      12 lead ECG CPVT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=related_link\">",
"      Atrial flutter: Epidemiology, classification, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18308?source=related_link\">",
"      Basic approach to delayed intraventricular conduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=related_link\">",
"      Clinical manifestations and diagnosis of Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=related_link\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_33_15898="Fever in children with chemotherapy-induced neutropenia";
var content_f15_33_15898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fever in children with chemotherapy-induced neutropenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/33/15898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15898/contributors\">",
"     Nabil M Ahmed, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15898/contributors\">",
"     Patricia M Flynn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/33/15898/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15898/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15898/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/33/15898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/33/15898/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/33/15898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is a major cause of morbidity and mortality in cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/1\">",
"     1",
"    </a>",
"    ]. Fever may be the first manifestation of a life-threatening infection, particularly during periods of neutropenia. Febrile episodes occur in approximately one-third of neutropenic episodes in children with chemotherapy-induced neutropenia or after hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/2\">",
"     2",
"    </a>",
"    ]. The approximate rate of occurrence is 0.76 episodes per every 30 days of neutropenia.",
"   </p>",
"   <p>",
"    The demonstration of markedly reduced infection-related morbidity and mortality with the empiric use of broad-spectrum antibiotics during periods of febrile neutropenia was a major advance in the field of oncology in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Subsequent studies identified factors associated with a higher risk of bacterial infection and facilitated a more tailored approach to empiric therapy.",
"   </p>",
"   <p>",
"    Because of important differences between oncology and hematology patients with neutropenia, fever in the pediatric cancer patient during periods of therapy-induced neutropenia are reviewed here. The types of infections and management of fever in the child with other forms of neutropenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link\">",
"     \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"     \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever in adult cancer patients with neutropenia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23804302\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia is strictly defined as an absolute neutrophil count (ANC) &lt;1500",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    The ANC is calculated using the following formula:",
"   </p>",
"   <p>",
"    ANC = total white blood cell count",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    x (percent neutrophils + percent bands) &divide; 100",
"   </p>",
"   <p>",
"    For purposes of management of the febrile pediatric cancer patient, neutropenia is defined as an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or an ANC that is expected to decrease to &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    during the next 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative risk of infection is related to both the degree and duration of neutropenia. An increased risk becomes apparent at an ANC &lt;1000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    is greater at an ANC &le;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and greatest at an ANC &le;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (profound neutropenia) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Patients with neutropenia projected to last for more than seven days also are at a higher risk of infection than are those with neutropenia of shorter duration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with hematologic malignancies that impair phagocytosis and killing of pathogens also are at increased risk of infection even if their ANC is normal (&ldquo;functional neutropenia&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]. Other factors that predispose to infection in association with chemotherapy include breakdown of skin and mucosal barriers, such as mucositis following",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    treatment, and altered humoral and cellular immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infections in pediatric cancer patients are more common during periods of chemotherapy-induced neutropenia, but they also can occur in the absence of neutropenia. For example, 90 percent of pediatric oncology patients have central venous catheters, which may be a source of infection whether or not the child is neutropenic. Because children are not always able to convey localized complaints, children with cancer who develop fever must be evaluated for infections regardless of the ANC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever generally is defined as a single oral temperature &ge;38.3&ordm;C (101&ordm;F) in neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/10\">",
"     10",
"    </a>",
"    ]. A temperature &ge;38&ordm;C (100.4&ordm;F) for longer than one hour or two elevations &gt;38&ordm;C (100.4&ordm;F) during a 12-hour period are additional definitions of fever that may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral temperature measurements are preferred, although an axillary temperature is acceptable if the patient is unable to use an oral thermometer. Generally, no conversion is made between axillary and oral temperatures. However, more conservative guidelines suggest that adding 0.5&ordm;F (0.3&ordm;C) to the axillary temperature reading may be warranted. Rectal temperature measurement should be avoided in neutropenic patients because of associated risks of mucosal trauma and bacteremia.",
"   </p>",
"   <p>",
"    Fever often is the sole sign of occult infection in the neutropenic host [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]. However, this sign may be absent in some infected patients who instead may be hypothermic, hypotensive, listless, or confused. Thus, infection must be considered and treated empirically if any signs of clinical deterioration are present in a neutropenic child, regardless of the recorded temperature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165385902\">",
"    <span class=\"h2\">",
"     Risk category",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fever and neutropenia can be divided into high- and low-risk categories based upon presenting signs and symptoms, counts, underlying cancer, type of therapy and the anticipated length of neutropenia, and medical comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]. However, there is no currently agreed-upon risk stratification specifically for children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165385930\">",
"    <span class=\"h3\">",
"     High-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk patients have an increased risk of severe infection. Patients with any of the following should be considered as high-risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutropenia (ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      anticipated to last &gt;7 days. Although the 2010 Infectious Diseases Society of America (IDSA) guidelines define patients as high-risk if they have profound neutropenia (ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      anticipated to last &gt;7 days [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"       6",
"      </a>",
"      ], we have opted to define high-risk as neutropenia (ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      anticipated to last &gt;7 days. Formal studies to clearly differentiate between patients with an ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are lacking.",
"     </li>",
"     <li>",
"      Evidence of hepatic insufficiency (aminotransferase levels &gt;5 times normal values) or renal insufficiency (creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"     </li>",
"     <li>",
"      Comorbid medical problems including, but not limited to:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Oral or gastrointestinal mucositis that interferes with swallowing or causes diarrhea",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms, including abdominal pain, nausea, vomiting, or diarrhea",
"     </li>",
"     <li>",
"      New-onset neurologic or mental status changes",
"     </li>",
"     <li>",
"      Intravascular catheter infection (especially catheter tunnel infection)",
"     </li>",
"     <li>",
"      New pulmonary infiltrate or hypoxemia or underlying chronic lung disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with infant acute lymphoblastic leukemia, acute myeloid leukemia, or within 30 days of hematopoietic stem cell transplant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Multiple Association for Supportive Care in Cancer (MASCC) score may be used to formally assess risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with MASCC score &lt;21 are at high risk. However, the utility of the MASCC Risk-Index score in pediatric patients is questionable since it was derived from persons older than 16 years and is influenced by chronic medical conditions, such as chronic obstructive pulmonary disease, diabetes, and congestive heart failure that are uncommon in children.",
"   </p>",
"   <p>",
"    High-risk patients should be admitted to the hospital for empiric antimicrobial therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef60657 \" href=\"UTD.htm?40/56/41856\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165385950\">",
"    <span class=\"h3\">",
"     Low-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-risk patients are those with [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neutropenia expected to resolve within seven days",
"     </li>",
"     <li>",
"      Stable and adequate hepatic and renal function",
"     </li>",
"     <li>",
"      No active comorbidities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Carefully selected low-risk patients may be candidates for oral empiric therapy or outpatient treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of documented infection, when a child presents with fever and therapy-induced neutropenia, ranges between 10 and 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/2,15-17\">",
"     2,15-17",
"    </a>",
"    ]. No clinical or microbiologic evidence of infection will be established in the remainder. Bacteremia is the most common form of documented infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. Other sites of infection include the gastrointestinal tract, with oral or intestinal mucositis or diarrhea caused by organisms such as",
"    <em>",
"     Clostridium difficile",
"    </em>",
"    and",
"    <em>",
"     Salmonella",
"    </em>",
"    spp; upper and lower respiratory tract; urinary tract; and skin and soft tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/1,15\">",
"     1,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of bacteremia vary greatly (range approximately 20 to 50 percent) depending upon the institution and underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/16-20\">",
"     16-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both gram-positive and gram-negative organisms are isolated frequently from the blood in febrile neutropenic children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/2,17,21\">",
"     2,17,21",
"    </a>",
"    ]. The frequency of pathogenic organisms varies from institution to institution. In general, there is a global shift toward a dominance of gram-positive organisms due to the ubiquitous use of prophylactic antimicrobials and indwelling venous catheters. The most common gram-positive pathogens are coagulase-negative staphylococci, viridans streptococci, and",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (including methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/2,17,20\">",
"     2,17,20",
"    </a>",
"    ]. Aerobic gram-negative bacilli account for approximately one-third to one-half of bacteremic episodes, with",
"    <em>",
"     Escherichia coli",
"    </em>",
"    ,",
"    <em>",
"     Klebsiella",
"    </em>",
"    spp,",
"    <em>",
"     Pseudomonas",
"    </em>",
"    spp,",
"    <em>",
"     Acinetobacter",
"    </em>",
"    spp, and",
"    <em>",
"     Enterobacter",
"    </em>",
"    spp among the more common isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/2,17,20\">",
"     2,17,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungi, typically",
"    <em>",
"     Candida",
"    </em>",
"    spp, are more likely to be recovered after prolonged courses of broad-spectrum antibiotics but occasionally may be the primary pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/2\">",
"     2",
"    </a>",
"    ]. Other potential fungal organisms include",
"    <em>",
"     Aspergillus",
"    </em>",
"    spp,",
"    <em>",
"     Phycomycetes",
"    </em>",
"    , and",
"    <em>",
"     Cryptococcus",
"    </em>",
"    spp [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"    <em>",
"     Fusarium",
"    </em>",
"    spp also have been increasingly recognized in these hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/24\">",
"     24",
"    </a>",
"    ]. The increasing use of antifungal prophylaxis is likely to shift the distribution of fungal isolates away from",
"    <em>",
"     Candida",
"    </em>",
"    spp and toward mold infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/25\">",
"     25",
"    </a>",
"    ]. This is particularly true in bone",
"    <span class=\"nowrap\">",
"     marrow/stem",
"    </span>",
"    cell transplant recipients.",
"   </p>",
"   <p>",
"    The most significant viral etiologies are herpes simplex and varicella-zoster virus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/17,26,27\">",
"     17,26,27",
"    </a>",
"    ]. Respiratory viruses are also frequently detected in nasopharyngeal aspirates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/17,27-30\">",
"     17,27-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is a major cause of morbidity and mortality in cancer patients. Serious infection may occur in the absence of fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neutropenia and must be considered in the pediatric cancer patient who is febrile and neutropenic; febrile but not neutropenic; or neutropenic and afebrile with signs of infection or clinical deterioration.",
"   </p>",
"   <p>",
"    Prompt initiation of empiric therapy can be life-saving, so rapid (but thorough) evaluation is critical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176622907\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history in a child with fever and neutropenia include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      New site-specific symptoms",
"     </li>",
"     <li>",
"      Antimicrobial prophylaxis",
"     </li>",
"     <li>",
"      Infection exposures",
"     </li>",
"     <li>",
"      History of documented infections or colonization",
"     </li>",
"     <li>",
"      Concomitant noninfectious cause of fever (eg, receipt of blood products)",
"     </li>",
"     <li>",
"      Underlying comorbid conditions (eg, diabetes, recent surgery)",
"     </li>",
"     <li>",
"      Presence of intravascular catheters or other devices",
"     </li>",
"     <li>",
"      Previous chemotherapy, agents used, and the stage of therapy (to anticipate the length of the neutropenic episode)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful physical examination should be performed with particular attention paid to those sites most commonly infected, including [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal vital signs, particularly tachycardia (even without hypotension)",
"     </li>",
"     <li>",
"      Skin, especially folds, areas surrounding nail beds, central venous line exit sites and subcutaneous tunnel, if present, and sites of bone marrow aspiration and lumbar puncture",
"     </li>",
"     <li>",
"      Sinuses",
"     </li>",
"     <li>",
"      Oropharynx, with attention to the gingiva",
"     </li>",
"     <li>",
"      Lungs",
"     </li>",
"     <li>",
"      Abdomen",
"     </li>",
"     <li>",
"      Perineum, particularly the perianal and labial regions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild erythema or tenderness should not be ignored because signs of inflammation in the neutropenic patient may be subtle. Repeated physical examinations are essential. Visual signs of inflammation may become evident only when neutrophil counts are recovering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176622864\">",
"    <span class=\"h2\">",
"     Laboratory tests and imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation for the child with fever and neutropenia should include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential and platelet count",
"     </li>",
"     <li>",
"      Electrolytes, creatinine, and blood urea nitrogen",
"     </li>",
"     <li>",
"      Liver transaminases and total bilirubin",
"     </li>",
"     <li>",
"      Blood cultures",
"     </li>",
"     <li>",
"      Cultures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      imaging of other sites of suspected infection as clinically indicated (described below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment should be initiated as soon as possible after cultures are obtained and should not be delayed while waiting for results or performing additional studies.",
"   </p>",
"   <p>",
"    Blood cultures should be obtained without delay. Blood cultures should be taken from each lumen of the central line when such access is available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/13\">",
"     13",
"    </a>",
"    ]. Opinions vary as to whether blood should be cultured from peripheral sites, as well [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The rationale for culturing blood from both peripheral and central sites is to differentiate a catheter-related infection from a bacteremia from another source. A catheter-related bloodstream infection can be diagnosed if the colony count of microbes in blood obtained via the catheter hub is at least threefold greater than that obtained from the peripheral blood or if the culture obtained via the catheter hub becomes positive at least two hours before the peripheral blood when using a continuous read system. However, treatment recommendations for central catheter-related infections and for bacteremias from other sources are similar, and many institutions do not recommend the routine culturing of blood from peripheral sites in addition to central sites even though peripheral cultures are necessary to confirm a diagnosis of catheter-related bloodstream infection. Peripheral cultures may guide decisions about whether to retain or remove a catheter.",
"   </p>",
"   <p>",
"    Obtaining more than one blood culture is helpful in the interpretation of blood culture results. If coagulase-negative staphylococci are isolated from two or more blood cultures, true bacteremia is more likely than contamination of the specimen, which may be reflected by a single positive blood culture. When obtaining blood from a central venous catheter, the importance of sampling all lumens is supported by studies in which 32 to 43 percent of positive cultures from double lumen catheters were positive from only one of multiple lumens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. In addition, comparison of microbe colony count or differential time to positivity can be used to diagnose a catheter-related blood stream infection in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the child remains febrile after initiation of empiric antibiotic therapy, daily blood cultures should be obtained for the next two days, after which blood cultures should be repeated when there is a change in clinical status [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]. Blood cultures also should be repeated if fever recurs following initial defervescence in response to empiric antibiotic therapy.",
"   </p>",
"   <p>",
"    In addition to the blood, it may be useful to culture urine in febrile, neutropenic girls. In one study, urinary tract infections accounted for 11 percent of all documented infections in febrile neutropenic patients, and 76 percent of those occurred in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/1\">",
"     1",
"    </a>",
"    ]. Additional studies should be obtained only as clinically indicated. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest radiographs in children with respiratory signs and symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/13,36,37\">",
"       13,36,37",
"      </a>",
"      ]. A chest radiogram that is negative for infiltrates should be interpreted with caution because infiltrates might appear with a delay or only when neutrophil counts are recovering.",
"     </li>",
"     <li>",
"      Abdominal imaging (radiographs or computed tomography)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasonography in children with abdominal signs and symptoms, particularly abdominal pain.",
"     </li>",
"     <li>",
"      Lumbar puncture for altered mental status or meningeal signs; platelet transfusion may be necessary before lumbar puncture in patients with thrombocytopenia.",
"     </li>",
"     <li>",
"      <em>",
"       C. difficile",
"      </em>",
"      toxin assay should be performed in patients with diarrhea. Although usually of limited value, stool culture, stool for viral particles, ova, parasites, and viral cultures should be considered if the clinical presentation is suggestive of infection.",
"     </li>",
"     <li>",
"      Culture and Gram stain of drainage from any site with drainage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23804521\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of therapy for the febrile, neutropenic patient is prompt initiation of empiric broad-spectrum antibiotics. General guidelines have been published for the use of empiric antibiotics during episodes of fever and neutropenia, including those published by the Infectious Diseases Society of America (IDSA), most recently updated in 2010, and the International Pediatric Fever and Neutropenia Guideline Panel, released in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,13\">",
"     6,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Empiric antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 IDSA and 2012 International Pediatric Fever and Neutropenia Guideline Panel guidelines provide suggestions for empiric antibiotics in neutropenic patients with cancer (",
"    <a class=\"graphic graphic_algorithm graphicRef60657 \" href=\"UTD.htm?40/56/41856\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. However, they are only meant to be guidelines, and treatment must be individualized for each patient (eg, those at risk for infections with resistant organisms).",
"   </p>",
"   <p>",
"    The guidelines emphasize that, when choosing empiric therapy, each practitioner should consider [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether the child is at high or low risk of infection (see",
"      <a class=\"local\" href=\"#H165385902\">",
"       'Risk category'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      The types of bacterial isolates found in the institution",
"     </li>",
"     <li>",
"      Antibiotic susceptibility patterns",
"     </li>",
"     <li>",
"      Drug allergies of the patient, if any",
"     </li>",
"     <li>",
"      Presence of organ dysfunction, particularly renal and hepatic",
"     </li>",
"     <li>",
"      The particular chemotherapeutic regimen and when it was administered: for example, an association exists between viridans streptococcal infection and high-dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=see_link\">",
"       cytarabine",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Whether the patient was receiving prophylactic antimicrobials",
"     </li>",
"     <li>",
"      Previous colonization with resistant bacteria (eg, methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      [MRSA];",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      -resistant enterococcus; extended-spectrum beta-lactamase producing organism, including",
"      <em>",
"       Klebsiella pneumoniae",
"      </em>",
"      carbapenemase)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bacterial infections in neutropenic cancer patients may be caused by either gram-positive or gram-negative organisms, and thus, empiric antibiotic therapy must be effective against a broad spectrum of potential pathogens. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Etiology of fever'",
"    </a>",
"    above.) For patients in whom a site of infection is defined, therapy can be adjusted from broad-spectrum to the most appropriate treatment for the particular infection once the patient has become afebrile [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5409836\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H357881953\">",
"    <span class=\"h4\">",
"     Suggested regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy with a broad-spectrum antipseudomonal beta-lactam (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"     cefepime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ), a carbapenem (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    or imipenem-cilastin), or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    is recommended for uncomplicated episodes of fever in neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. Randomized controlled trials and a systematic review have demonstrated that empiric monotherapy with these agents is as efficacious as combination therapy but with fewer adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommended agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       Cefepime",
"      </a>",
"      &ndash; 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously (IV) every 8 hours up to a maximum of 2 g per dose;",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      &ndash; 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours up to a maximum of 2 g per dose; adjust dose for renal dysfunction;",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       Meropenem",
"      </a>",
"      &ndash; For children &ge;3 months of age: 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours up to a maximum of 1 g per dose for non-central nervous system infections and 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours up to a maximum of 2",
"      <span class=\"nowrap\">",
"       g/dose",
"      </span>",
"      for central nervous system infections; adjust dose for renal dysfunction;",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/39/11896?source=see_link\">",
"       Imipenem-cilastatin",
"      </a>",
"      &ndash; 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 6 hours up to a maximum of 1 g per dose for infants older than one month of age and children; adjust dose for renal dysfunction,",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/10/33956?source=see_link\">",
"        Piperacillin",
"       </a>",
"       /tazobactam",
"      </span>",
"      &ndash; For infants &lt;9 months: 80",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of piperacillin component IV every 8 hours; for infants and children &ge;9 months and &le;40 kg: 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of piperacillin component IV every 8 hours; for children &gt;40 kg: 3 g of piperacillin component IV every 6 hours or 4 g of piperacillin component IV every 6 to 8 hours; the maximum daily dose of the piperacillin component is 16",
"      <span class=\"nowrap\">",
"       g/day;",
"      </span>",
"      adjust dose for renal dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a carbapenem is to be used,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    is preferred because of the risk of seizures with imipenem-cilastin.",
"   </p>",
"   <p>",
"    Additional antimicrobials may be added to the initial regimen based on the clinical presentation, suspected antimicrobial resistance, or for management of complications. As an example, if abdominal symptoms are present, particularly abdominal pain or blood per rectum,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    should be added if the initial combination does not adequately cover anaerobic organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Likewise, if infection with MRSA is suspected, the addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    may be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is not routinely recommended in the initial empiric regimen for patients with fever and neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]. It should be reserved for children with clear indications for gram-positive coverage.",
"   </p>",
"   <p>",
"    Although up to two-thirds of bacterial isolates from blood in febrile neutropenic cancer patients are gram-positive cocci, frequently coagulase-negative staphylococci resistant to extended-spectrum penicillins or third-generation cephalosporins, the morbidity and mortality have not differed in patients treated with or without",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    in the initial antibiotic regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Infections with alpha-hemolytic streptococci may be an exception to this observation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    as part of empiric therapy of febrile neutropenia is discouraged to decrease colonization or infection with vancomycin-resistant enterococci (VRE). Many institutions have implemented guidelines for the use of vancomycin recommended by the Hospital Infection Control Practices Advisory Committee of the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/48\">",
"     48",
"    </a>",
"    ]. These restrictions include using vancomycin in febrile neutropenic patients only when there is a strong suspicion of infection with a gram-positive organism.",
"   </p>",
"   <p>",
"    The 2010 guidelines from the IDSA recommend that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    be reserved for the following clinical scenarios [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypotension or other signs of cardiopulmonary deterioration",
"     </li>",
"     <li>",
"      Radiographically documented pneumonia",
"     </li>",
"     <li>",
"      Clinically suspected central venous line site infection (eg, chills or rigors with infusion through the catheter and cellulitis around the catheter entry or exit site)",
"     </li>",
"     <li>",
"      Skin or soft tissue infection at any site",
"     </li>",
"     <li>",
"      Known colonization with MRSA, penicillin- and cephalosporin-resistant",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"     </li>",
"     <li>",
"      When a blood culture has been reported to be growing gram-positive bacteria and identification and susceptibility testing are pending",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional indications for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Substantial mucositis",
"     </li>",
"     <li>",
"      Prophylaxis with quinolones during afebrile neutropenia",
"     </li>",
"     <li>",
"      Previous history of infection with penicillin-resistant streptococci",
"     </li>",
"     <li>",
"      Recent intensive chemotherapy associated with a high risk for infection with such organisms (eg, alpha-hemolytic streptococcal infection following high-dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=see_link\">",
"       cytarabine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    is added to the empiric regimen for one of the above indications and susceptible bacteria are not recovered from the patient within two to three days, vancomycin should be discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]. Vancomycin can be associated with nephrotoxicity; kidney function should be strictly monitored. Vancomycin levels are warranted for patients with renal dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1660595789\">",
"    <span class=\"h4\">",
"     Aminoglycosides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminoglycosides are not recommended for initial therapy for febrile neutropenic cancer patients. However, they may be added to the initial regimen in the presence of complications (eg, hypotension and pneumonia) or if there is a suspicion of antimicrobial resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]. Documented gram-negative bloodstream infections can also be initially treated with combination therapy of a beta-lactam or carbapenem plus an aminoglycoside. Once the patient is stable and the susceptibilities are known, the aminoglycoside may be discontinued. Aminoglycoside monotherapy should not be used either as empiric coverage or treatment because of the rapid development of resistance. Aminoglycosides are associated with oto- and nephrotoxicity and levels and kidney function should be strictly monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H397731596\">",
"    <span class=\"h4\">",
"     Initial oral therapy for low-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it has not been well-studied in children,",
"    <strong>",
"    </strong>",
"    the combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    is an option for combination therapy for low-risk patients who are candidates for oral empiric therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,49-51\">",
"     6,49-51",
"    </a>",
"    ]. In two randomized trials, the rate of treatment failure and duration of fever, neutropenia, and antimicrobial therapy were similar in patients treated with oral",
"    <span class=\"nowrap\">",
"     ciprofloxacin/amoxicillin-clavulanate",
"    </span>",
"    versus intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"     cefepime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/49,51\">",
"     49,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H397731673\">",
"    <span class=\"h2\">",
"     Modifications of initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initiation of the initial antimicrobial regimen, patients should be monitored closely. Modification of the regimen may be warranted based upon a variety of clinical scenarios, including (",
"    <a class=\"graphic graphic_algorithm graphicRef74452 \" href=\"UTD.htm?0/14/225\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Change in clinical status or vital signs",
"     </li>",
"     <li>",
"      Isolation of a blood-borne organism",
"     </li>",
"     <li>",
"      Documented clinical or microbiologic infection",
"     </li>",
"     <li>",
"      Development of signs or symptoms of a localized infection",
"     </li>",
"     <li>",
"      Persistent fever for more than four days (",
"      <a class=\"graphic graphic_algorithm graphicRef53163 \" href=\"UTD.htm?11/47/12017\">",
"       algorithm 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Recurrent fever after initial defervescence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23804813\">",
"    <span class=\"h2\">",
"     Antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungi are not often isolated as the initial cause of fever and neutropenia but are often in the differential diagnosis of persistent or recurrent fever. Clinically occult fungal infection must be considered in children with persistent fever (ie, &ge;4 days) and neutropenia despite empiric antibacterial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/13,52\">",
"     13,52",
"    </a>",
"    ]. Additional risks for invasive fungal infection include acute myeloid leukemia, relapsed acute leukemia, highly myelosuppressive chemotherapy, and allogeneic hematopoietic cell transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/13,25,52-56\">",
"     13,25,52-56",
"    </a>",
"    ]. A variety of fungi can cause infection in cancer patients, and early diagnosis can be difficult.",
"   </p>",
"   <p>",
"    The 2010 IDSA guidelines and the 2012 International Pediatric Fever and Neutropenia Guidelines indicate that the addition of empiric antifungal therapy may be warranted for high-risk patients who have persistent fever after four to seven days of broad-spectrum antibiotics and no identified source of fever [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. Routine use of empiric antifungal therapy is not recommended for low-risk patients. Before initiating antifungal therapy, suggested evaluations of the patient may include computed tomography (CT) of the chest and sinuses, serial fungal serology (eg, galactomannan), and biopsy of any suspicious lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. Beta-D glucan is not recommended in children because its diagnostic accuracy has not been demonstrated in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric antifungal therapy is usually continued until resolution of neutropenia in the absence of evidence of invasive fungal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/13\">",
"     13",
"    </a>",
"    ]. However, there is little evidence to guide this decision.",
"   </p>",
"   <p>",
"    Antifungal therapy is supported by a randomized, placebo-controlled trial in which empiric intravenous administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    early in the course of febrile neutropenia was effective in the control of clinically occult fungal invasion and in the prevention of fungal superinfections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the potential benefits of empiric",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    therapy, its use is limited by substantial toxicity, particularly nephrotoxicity. Potentially less toxic alternatives include lipid formulations of amphotericin B (liposomal amphotericin or amphotericin B colloidal dispersion), echinocandins (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=see_link\">",
"     caspofungin",
"    </a>",
"    ), and triazole derivatives (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/60/12234?source=see_link\">",
"     voriconazole",
"    </a>",
"    ). The IDSA guidelines indicate that there is insufficient information to suggest a preferred first-line antifungal agent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ]. Lipid formulations of amphotericin B often are used in children. The 2012 International Pediatric Fever and Neutropenia Guidelines recommend either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    or caspofungin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/13\">",
"     13",
"    </a>",
"    ]. However, if lipid formulations of amphotericin B are not available, amphotericin B deoxycholate is acceptable. In children receiving antifungal prophylaxis with an amphotericin B formulation, an antifungal from a different class should be used as empiric therapy.",
"   </p>",
"   <p>",
"    Pooled analysis of four randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/57-60\">",
"     57-60",
"    </a>",
"    ] found lipid formulations of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    to have similar rates of breakthrough fungal infections, but less nephrotoxicity and infusion-related toxicity (liposomal formulations) than conventional amphotericin B [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/47/21237?source=see_link\">",
"     Caspofungin",
"    </a>",
"    is approved by the US Food and Drug Administration for the treatment of fever and neutropenia in children &ge;3 months. However, data regarding its safety and efficacy in children with fever and neutropenia are limited. A multicenter randomized trial comparing caspofungin with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    in 82 children with persistent fever and neutropenia found that the two agents had similar response rates and adverse effects, including infusion-related toxicity and nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/62\">",
"     62",
"    </a>",
"    ]. However, the trial was not powered to detect statistically significant differences. Further study is indicated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/60/12234?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is another antifungal agent that has been insufficiently studied in children with fever and neutropenia. A systematic review of two trials comparing voriconazole with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    found",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    to be more effective than voriconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of empiric antibiotic therapy depends upon the clinical circumstances of the individual patient. The traditional endpoint has been negative blood cultures for at least 48 hours, resolution of fever for at least 24 hours, and resolution of neutropenia (ie, absolute neutrophil count [ANC] &gt;500",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,13,64\">",
"     6,13,64",
"    </a>",
"    ]. However, investigators have studied risk factors for the development of serious infection in an effort to reduce the length of time of hospitalization (if any) and the length of therapy in children and adolescents with low risk for significant complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/15,17,65-67\">",
"     15,17,65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with prolonged neutropenia (ie, more than seven days) generally are considered at relatively high risk for both bacterial and fungal infections. However, retrospective review of 33 children with prolonged neutropenia from one institution demonstrated that such patients can be discharged safely before resolution of the neutropenia if they appeared well, were afebrile for at least 24 hours, had sterile blood cultures, had any local infection under control, and showed evidence of bone marrow recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/18,66\">",
"     18,66",
"    </a>",
"    ]. Bone marrow recovery was defined as any sustained increase in platelet count and ANC or absolute phagocyte count (APC = ANC + absolute monocyte count). These investigators also showed that patients with either transient or prolonged neutropenia could be discharged safely from the hospital with antibiotics discontinued when they met the above criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Similar criteria are used to guide decisions on the appropriate duration of therapy at other institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from a small retrospective study suggest that patients who are afebrile for at least 24 hours, are in good clinical condition, have been treated with intravenous antibiotics for a minimum of 72 hours, and have no identified infectious source can be discharged from the hospital without antibiotics before evidence of marrow recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/13,68\">",
"     13,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Colony stimulating factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2582454\">",
"    <span class=\"h3\">",
"     Prophylactic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children treated for cancer in the United States are treated on research protocols, and many of the intensive chemotherapy regimens incorporate the use of granulocyte-colony stimulating factor (G-CSF) immediately after courses of chemotherapy. Potential benefits of prophylactic G-CSF or granulocyte-monocyte colony stimulating factor (GM-CSF) include a reduction in the duration of neutropenia and, in theory, the risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most pediatric studies have demonstrated that prophylactic use of G-CSF reduces the duration of neutropenia, conclusions about its impact on rates of febrile neutropenia, days of fever, days of intravenous antibiotic use, rates of documented infection, and lengths of hospital stay have conflicted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. The conflicting results may reflect differences in the myelosuppressive intensity of the various chemotherapy regimens, one of many variables among the different studies. In a meta-analysis of 16 randomized, controlled trials of the prophylactic use of CSFs in children, CSFs were associated with a 20 percent reduction in febrile neutropenia and an approximately two-day decrease in hospitalization duration, but no difference in parenteral IV antibiotic therapy or infection-related mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010 IDSA guidelines for neutropenic patients indicate that prophylactic use of CSFs may be warranted for patients in whom the anticipated risk of fever and neutropenia is &ge;20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2582461\">",
"    <span class=\"h3\">",
"     Interventional use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant benefits from initiating CSFs in the midst of febrile neutropenia have not been firmly established. In a randomized study of 186 episodes of febrile neutropenia in pediatric cancer patients, a small but statistically significant reduction in the length of hospital stay (five versus seven days) and days of intravenous antibiotic use (five versus six days) was observed with administration of G-CSF compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/75\">",
"     75",
"    </a>",
"    ]. In another randomized trial in 66 patients with chemotherapy-induced febrile neutropenia (59 with acute lymphoblastic leukemia), those treated with G-CSF had shorter median time to resolution of neutropenia (4 versus 13 days), but no significant differences in duration of fever or antibiotic treatment, addition of antifungal therapy, or incidence of shock [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/76\">",
"     76",
"    </a>",
"    ]. Comparable, modest results were obtained in a study evaluating the effect of the addition of GM-CSF during episodes of fever and neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether high-risk patients (see",
"    <a class=\"local\" href=\"#H165385930\">",
"     'High-risk'",
"    </a>",
"    above)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with predicted prolonged courses of neutropenia (ie, more than 7 days) might benefit from the use of G-CSF remains unanswered. Nonetheless, interventional G-CSF may be warranted for children with complicated episodes of fever and neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Outpatient management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient management of fever and neutropenia with intravenous or oral antibiotics may be an option for carefully selected low-risk patients if daily follow-up is ensured [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/6,13\">",
"     6,13",
"    </a>",
"    ] . Several studies using strict eligibility criteria suggest that outpatient treatment may be safe and appropriate for children at low risk of serious infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/81-84\">",
"     81-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study, hypotension, requirement for fluid resuscitation, and a diagnosis of leukemia or lymphoma correlated with an increased probability of bacteremia and persistent fever and ANC &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    after 48 hours of empiric therapy were associated with a high risk of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/15\">",
"     15",
"    </a>",
"    ]. Based upon these observations, the investigators suggested that children who initially present without signs of sepsis and who are afebrile and have an ANC &gt;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    after 48 hours of empiric therapy could be considered for early hospital discharge, with continuation of outpatient antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another retrospective review of 33 children with prolonged neutropenia demonstrated that such patients can be discharged safely before resolution of the neutropenia if they appeared well, were afebrile for at least 24 hours, had sterile blood cultures, had any local infection under control, and showed evidence of bone marrow recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/33/15898/abstract/66\">",
"     66",
"    </a>",
"    ]. Bone marrow recovery was defined as any sustained increase in platelet count and ANC or absolute phagocyte count (APC = ANC + absolute monocyte count).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184978076\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection is a major cause of morbidity and mortality in cancer patients. Fever may be the first manifestation of a life-threatening infection, particularly during periods of neutropenia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neutropenia, for the purpose of management of the febrile pediatric cancer patient, is defined as an absolute neutrophil count (ANC) of &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      or an ANC that is expected to decrease to &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      during the next 48 hours. In neutropenic patients, fever is defined as a single oral temperature &ge;38.3&ordm;C (101&ordm;F), a temperature &ge;38&ordm;C (100.4&ordm;F) for longer than one hour, or two elevations &gt;38&ordm;C (100.4&ordm;F) during a 12-hour period. (See",
"      <a class=\"local\" href=\"#H23804302\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with fever and neutropenia can be categorized as high- or low-risk for severe infection based upon presenting signs and symptoms, ANC, underlying cancer, type of therapy, and medical comorbidities. High-risk is defined by neutropenia (ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      anticipated to last &gt;7 days; hepatic or renal insufficiency; or comorbid medical problems. Low-risk is defined by neutropenia expected to resolve within 7 days; stable and adequate hepatic and renal function; and no active comorbidities. (See",
"      <a class=\"local\" href=\"#H165385902\">",
"       'Risk category'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Between 10 and 40 percent of children with fever and chemotherapy-induced neutropenia have a documented infection. Bloodstream infections are the most common and may be caused by gram-positive organisms, gram-negative organisms, or fungi. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology of fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection is a major cause of morbidity and mortality in cancer patients. Serious infection may occur in the absence of fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neutropenia and must be considered in the pediatric cancer patient who is febrile and neutropenic; febrile but not neutropenic; or neutropenic and afebrile with signs of infection or clinical deterioration. Prompt initiation of empiric therapy can be life-saving, so rapid (but thorough) evaluation is critical (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history include new site-specific symptoms, antimicrobial prophylaxis, infection exposures, recent infections or colonizations, underlying comorbid conditions, and noninfectious causes of fever (eg, receipt of blood products). (See",
"      <a class=\"local\" href=\"#H176622907\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Areas of particular interest on the physical examination include the skin (especially skin folds, nail beds, central line sites, and sites of recent procedures such as bone marrow aspiration or lumbar puncture); sinuses; oropharynx, including the gums; lungs; abdomen; and perineum. Mild erythema or tenderness may be important clues to infection. The physical examination must be repeated at least daily after initiation of empiric antimicrobial therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       laboratory/imaging",
"      </span>",
"      evaluation of the child with fever and neutropenia should include (at minimum) (see",
"      <a class=\"local\" href=\"#H176622864\">",
"       'Laboratory tests and imaging'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete blood count with differential and platelet count",
"     </li>",
"     <li>",
"      Electrolytes, creatinine, and blood urea nitrogen",
"     </li>",
"     <li>",
"      Liver transaminases and total bilirubin",
"     </li>",
"     <li>",
"      Blood cultures",
"     </li>",
"     <li>",
"      Cultures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      imaging of other sites of suspected infection as clinically indicated; treatment should not be delayed while awaiting results",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2010 Infectious Disease Society of America guidelines for antimicrobial agents in neutropenic patients with cancer provides suggestions for initial empiric antibiotic selection (",
"      <a class=\"graphic graphic_algorithm graphicRef60657 \" href=\"UTD.htm?40/56/41856\">",
"       algorithm 1",
"      </a>",
"      ), modification of the empiric regimen during days two to four of therapy (",
"      <a class=\"graphic graphic_algorithm graphicRef74452 \" href=\"UTD.htm?0/14/225\">",
"       algorithm 2",
"      </a>",
"      ), and management of high-risk patients with fever for more than four days (",
"      <a class=\"graphic graphic_algorithm graphicRef53163 \" href=\"UTD.htm?11/47/12017\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23804521\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monotherapy with a broad-spectrum antipseudomonal beta-lactam (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       cefepime",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"       ceftazidime",
"      </a>",
"      ), a carbapenem (eg, imipenem-cilastin or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      ), or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      is recommended for uncomplicated episodes of fever in neutropenic patients.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      should be reserved for children with clear indications for gram-positive coverage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Empiric antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric antifungal therapy may be warranted for high-risk patients who have persistent fever after four to seven days of broad-spectrum antibiotics and no identified source of fever. (See",
"      <a class=\"local\" href=\"#H23804813\">",
"       'Antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of empiric antibiotic therapy depends upon the clinical circumstances of the individual patient. Resolution of neutropenia is the traditional endpoint. Outpatient management of fever and neutropenia with intravenous or oral antibiotics may be an option for carefully selected low-risk patients if daily follow-up is ensured. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Duration of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Outpatient management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/1\">",
"      Auletta JJ, O'Riordan MA, Nieder ML. Infections in children with cancer: a continued need for the comprehensive physical examination. J Pediatr Hematol Oncol 1999; 21:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/2\">",
"      Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 2007; 45:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/3\">",
"      Bodey GP, Whitecar JP Jr, Middleman E, Rodriguez V. Carbenicillin therapy for pseudomonas infections. JAMA 1971; 218:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/4\">",
"      Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284:1061.",
"     </a>",
"    </li>",
"    <li>",
"     Koh AY, Pizzo PA. Infectious complications in pediatric cancer patients. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.1190.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/6\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/7\">",
"      Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/8\">",
"      Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/9\">",
"      Lehrnbecher T, Foster C, V&aacute;zquez N, et al. Therapy-induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Oncol 1997; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     Wolff LJ, Ablin AR, Altman AJ, Johnson FL. The management of fever. In: Supportive care of children with cancer: Current therapy and guidelines from the Children's Cancer Group, Ablin AR (Ed), Johns Hopkins University Press, Baltimore 1997. p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/11\">",
"      Klaassen RJ, Goodman TR, Pham B, Doyle JJ. \"Low-risk\" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/12\">",
"      Phillips RS, Lehrnbecher T, Alexander S, Sung L. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One 2012; 7:e38300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/13\">",
"      Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012; 30:4427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/14\">",
"      Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/15\">",
"      Lucas KG, Brown AE, Armstrong D, et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/16\">",
"      Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 1996; 14:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/17\">",
"      Hakim H, Flynn PM, Knapp KM, et al. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009; 31:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/18\">",
"      Ahmed N, El-Mahallawy HA, Ahmed IA, et al. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study. Pediatr Blood Cancer 2007; 49:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/19\">",
"      Roguin A, Kasis I, Ben-Arush MW, et al. Fever and neutropenia in children with malignant disease. Pediatr Hematol Oncol 1996; 13:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/20\">",
"      Agyeman P, Aebi C, Hirt A, et al. Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatr Infect Dis J 2011; 30:e114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/21\">",
"      Aquino VM, Pappo A, Buchanan GR, et al. The changing epidemiology of bacteremia in neutropenic children with cancer. Pediatr Infect Dis J 1995; 14:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/22\">",
"      Walsh TJ, Pizzo PA. Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol 1988; 42:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/23\">",
"      Pizzo PA, Walsh TJ. Fungal infections in the pediatric cancer patient. Semin Oncol 1990; 17:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/24\">",
"      Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/25\">",
"      Mor M, Gilad G, Kornreich L, et al. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011; 56:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/26\">",
"      Ramphal R, Grant RM, Dzolganovski B, et al. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J 2007; 26:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/27\">",
"      Katsimpardi K, Papadakis V, Pangalis A, et al. Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment. Support Care Cancer 2006; 14:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/28\">",
"      Lindblom A, Bhadri V, S&ouml;derh&auml;ll S, et al. Respiratory viruses, a common microbiological finding in neutropenic children with fever. J Clin Virol 2010; 47:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/29\">",
"      Torres JP, Labra&ntilde;a Y, Iba&ntilde;ez C, et al. Frequency and clinical outcome of respiratory viral infections and mixed viral-bacterial infections in children with cancer, fever and neutropenia. Pediatr Infect Dis J 2012; 31:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/30\">",
"      Suryadevara M, Tabarani CM, Bartholoma N, et al. Nasopharyngeal detection of respiratory viruses in febrile neutropenic children. Clin Pediatr (Phila) 2012; 51:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/31\">",
"      Adamkiewicz TV, Lorenzana A, Doyle J, Richardson S. Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 1999; 18:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/32\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/33\">",
"      Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2002; 24:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/34\">",
"      Robinson JL. Sensitivity of a blood culture drawn through a single lumen of a multilumen, long-term, indwelling, central venous catheter in pediatric oncology patients. J Pediatr Hematol Oncol 2002; 24:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/35\">",
"      Franklin JA, Gaur AH, Shenep JL, et al. In situ diagnosis of central venous catheter-related bloodstream infection without peripheral blood culture. Pediatr Infect Dis J 2004; 23:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/36\">",
"      Renoult E, Buteau C, Turgeon N, et al. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 2004; 43:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/37\">",
"      Korones DN. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 2004; 43:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/38\">",
"      Sotiropoulos SV, Jackson MA, Woods GM, et al. Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Pediatr Infect Dis J 1989; 8:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/39\">",
"      Paganini H, Staffolani V, Zubizarreta P, et al. Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors. Eur J Cancer 2003; 39:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/40\">",
"      De Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994; 120:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/41\">",
"      Hathorn JW, Rubin M, Pizzo PA. Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy. Antimicrob Agents Chemother 1987; 31:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/42\">",
"      Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/43\">",
"      Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003; :CD003038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/44\">",
"      Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/45\">",
"      Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991; 163:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/46\">",
"      Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 1999; 29:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/47\">",
"      Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/48\">",
"      Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/49\">",
"      Gupta A, Swaroop C, Agarwala S, et al. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol 2009; 31:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/50\">",
"      Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/51\">",
"      Cagol AR, Castro Junior CG, Martins MC, et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. J Pediatr (Rio J) 2009; 85:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/52\">",
"      Villarroel M, Avil&eacute;s CL, Silva P, et al. Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: a prospective multicenter evaluation. Pediatr Infect Dis J 2010; 29:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/53\">",
"      Castagnola E, Cesaro S, Giacchino M, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J 2006; 25:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/54\">",
"      Rosen GP, Nielsen K, Glenn S, et al. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 2005; 27:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/55\">",
"      Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117:e711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/56\">",
"      Groll AH, Kurz M, Schneider W, et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 1999; 42:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/57\">",
"      Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/58\">",
"      Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 2000; 22:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/59\">",
"      Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/60\">",
"      White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/61\">",
"      Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010; :CD006343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/62\">",
"      Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/63\">",
"      J&oslash;rgensen KJ, G&oslash;tzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006; :CD004707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/64\">",
"      Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/65\">",
"      Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol 2010; 28:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/66\">",
"      Aquino VM, Buchanan GR, Tkaczewski I, Mustafa MM. Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia. Med Pediatr Oncol 1997; 28:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/67\">",
"      Bash RO, Katz JA, Cash JV, Buchanan GR. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994; 74:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/68\">",
"      Lehrnbecher T, Stanescu A, K&uuml;hl J. Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection 2002; 30:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/69\">",
"      Clarke V, Dunstan FD, Webb DK. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med Pediatr Oncol 1999; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/70\">",
"      Michon JM, Hartmann O, Bouffet E, et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer 1998; 34:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/71\">",
"      Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/72\">",
"      Riikonen P, Rahiala J, Salonvaara M, Perkki&ouml; M. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 1995; 13:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/73\">",
"      Welte K, Reiter A, Mempel K, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-M&uuml;nster Study Group. Blood 1996; 87:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/74\">",
"      Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22:3350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/75\">",
"      Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997; 15:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/76\">",
"      Ozkaynak MF, Krailo M, Chen Z, Feusner J. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2005; 45:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/77\">",
"      Riikonen P, Saarinen UM, M&auml;kipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 1994; 13:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/78\">",
"      Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002; 116:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/79\">",
"      Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr 1998; 157:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/80\">",
"      Clark OA, Lyman G, Castro AA, et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003; :CD003039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/81\">",
"      Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/82\">",
"      Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/83\">",
"      Shenep JL, Flynn PM, Baker DK, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 2001; 32:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/33/15898/abstract/84\">",
"      Paganini H, G&oacute;mez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 2003; 97:1775.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6051 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15898=[""].join("\n");
var outline_f15_33_15898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H184978076\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23804302\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165385902\">",
"      Risk category",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H165385930\">",
"      - High-risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H165385950\">",
"      - Low-risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY OF FEVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176622907\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176622864\">",
"      Laboratory tests and imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23804521\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Empiric antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5409836\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H357881953\">",
"      Suggested regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vancomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1660595789\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H397731596\">",
"      Initial oral therapy for low-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H397731673\">",
"      Modifications of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23804813\">",
"      Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Colony stimulating factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2582454\">",
"      - Prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2582461\">",
"      - Interventional use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184978076\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6051\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6051|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/56/41856\" title=\"algorithm 1\">",
"      Neutropenic fever initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/14/225\" title=\"algorithm 2\">",
"      Neutropenic fever reassessment after 2 to 4 days",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/47/12017\" title=\"algorithm 3\">",
"      Fever neutropenia reassessment after four days",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=related_link\">",
"      Risk assessment of adults with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=related_link\">",
"      Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_33_15899="Short versus long acting CCBs";
var content_f15_33_15899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potentially harmful cardiovascular effects of short-acting calcium channel blockers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Short-acting nifedipine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Long-acting agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proischemic effect",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negative inotropic effect",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Effects on rhythm",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked hypotension",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reflex increase in sympathetic activity",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prohemorrhagic effects",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15899=[""].join("\n");
var outline_f15_33_15899=null;
var title_f15_33_15900="Approach to management of fetal tachycardia";
var content_f15_33_15900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors to consider prior to treatment of fetal tachycardia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Favoring treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Favoring observation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Favoring delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tachycardia rate",
"        </strong>",
"        (bpm)",
"       </td>",
"       <td>",
"        &gt;220",
"       </td>",
"       <td>",
"        &le;200",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Persistence",
"        </strong>",
"       </td>",
"       <td>",
"        &gt;50 percent of the day",
"       </td>",
"       <td>",
"        &le;20-25 percent of the day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gestational age",
"        </strong>",
"        (weeks)",
"       </td>",
"       <td>",
"        &lt;34",
"       </td>",
"       <td>",
"        &ge;34",
"       </td>",
"       <td>",
"        Term; mature lungs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hydrops",
"        </strong>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Preeclampsia",
"        </strong>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        For maternal safety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mechanism",
"        </strong>",
"       </td>",
"       <td>",
"        Atrial flutter",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Typical SVT",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Nonsustained ectopic atrial tachycardia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        PJRT (slow, frequently terminating)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BPM: beats per minute; SVT: supraventricular tachycardia; PJRT: persistent junctional reciprocating tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15900=[""].join("\n");
var outline_f15_33_15900=null;
var title_f15_33_15901="Time course of diuretic action";
var content_f15_33_15901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Steady state after initiation of a thiazide diuretic",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in sodium and potassium balance (intake minus excretion) after the administration of 100 mg of hydrochlorothiazide to 3 normal subjects. Negative balance persisted for only three days for sodium and six days for potassium before a steady state was reestablished in which intake and excretion were roughly equal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Maronde RF, Milgrom M, Vlachakis ND,&nbsp;et al.&nbsp;JAMA 1983; 249:237.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15901=[""].join("\n");
var outline_f15_33_15901=null;
var title_f15_33_15902="Treatment of HCV genotype I boceprevir";
var content_f15_33_15902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Treatment of HCV genotype I with boceprevir, peginterferon, and ribavirin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 287px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrows indicate time points where a viral load should be checked. A viral load should also be checked at the end of treatment and 6 months after the completion of treatment in patients with undetectable HCV RNA at the end of treatment.",
"    <div class=\"footnotes\">",
"     DT: dual therapy (peginterferon, weight-based ribavirin); TT: triple therapy (boceprevir, peginterferon, weight-based ribavirin).",
"     <br>",
"      * Treatment should be discontinued if the viral load at week 12 is &gt;100 IU/mL or if HCV RNA is detectable at week 24.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Patients with detectable HCV RNA at week 4 may benefit from a total 48 weeks of therapy. We suggest continuing treatment for 48 weeks in patients who are tolerating therapy.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15902=[""].join("\n");
var outline_f15_33_15902=null;
var title_f15_33_15903="Beta hemolysis 2";
var content_f15_33_15903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Streptococcus pyogenes on blood agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Culture of Streptococcus pyogenes on blood agar showing large zones of clear beta-hemolysis around the small colonies. The susceptibility of this organism to bacitracin is demonstrated by the zone of inhibition around the bacitracin-containing disc (A) on the left side of the plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_33_15903=[""].join("\n");
var outline_f15_33_15903=null;
